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Abstract
Melanoma is the deadliest form of skin cancer. Metastasis to the brain is a life-threatening
complication of melanoma in which the clinical incidence is 6-43%. Few animal models exist
for melanoma brain metastases, and many are not clinically relevant. MRI was implemented
to examine the development of tumors in a clinically relevant model of melanoma brain
metastases. Balanced steady-state free precession (b-SSFP) sequence was used to assess total
metastasis burden, T1wSE MRI using Gd-DTPA was used to assess blood-tumour barrier
(BTB) integrity in vivo and dextran perfusion was used to assess BTB leakiness in situ. This
model produced low tumour burden ranging from 5 to 19 metastases at endpoint, many
nonenhancing metastases were detected at early time points and there was considerable
heterogeneity in permeability of the BTB for melanoma brain metastases. This clinically
relevant model can be applied in future studies involving testing efficacy of
chemotherapeutic agents.

Keywords
Melanoma, clinically relevant, brain metastasis, balanced steady-state free precession
(bSSFP), magnetic resonance imaging (MRI), blood-tumour-barrier (BTB), enhancing,
nonenhancing, in vivo, metastasis burden, skin cancer, hematoxylin and eosin, mouse model,
gadolinium contrast agent (Gd-DTPA), micron-sized iron oxide (MPIO), 3 Tesla (3T), blood
brain barrier (BBB), intracardiac (IC) cell injection, Dextran Texas Red, ex vivo, in situ,
cellular MRI.

iii

Acknowledgments
I would first like to express my sincere gratitude, to the University of Western Ontario, for
the opportunity of pursuing my graduate studies in the Medical Biophysics program and, to
the Robarts Research Institute for providing the means for me to conduct this unique and
interesting research work.
I wish to foremost express my gratitude to my supervisor, mentor, friend and colleague Dr.
Paula Foster, who has inspired me to think beyond in regard to research and scholarship.
Through her leadership and guidance, I was motivated and excited to create and develop this
thesis, with her invaluable help and patience. This was a wonderful experience- working and
learning in your lab and for providing financial support for my project.
I would also like to thank the members of my research advisory committee: Dr. Ann
Chambers; and Dr. Giles Santyr, who insisted that I become inquisitive and curious during
my search, by looking at what other avenues should be explored in this project.
My day-to-day scanning requirements: In order that this research be completed on time; the
scanner required constant troubleshooting and replacement of parts for the mouse coils. For
this, I am indebted to Dr. Andrew Alejski, Thank you. In addition, I am thankful to Dr.
Francisco Martinez for the help in maintaining the chiller, which cools the gradient inserts.
Also, I would like to thank Dr. Brian Rutt for construction of the gradient insert; which was
heavily used in my MR imaging studies. And Trevor Szekeres for ensuring that the 3T is up
in a timely manner, and for timely notification of the system upgrades including 3T
downtime.
To my lab associates: Yuhua Chen (for assisting in cutting mouse brain tissue, performing
mice perfusions and histological imaging), Catherine McFadden (for assisting in cell
culturing of the melanoma cells and the preparation of these cells for intracardiac cell
injections), Dr. Emeline Ribot (for assisting with cell injections for the USPIO pilot project
and preparation of mice for gas anesthesia before intracardiac cell injections); Carmen
Simedrea (for your expertise in intracardiac cell injections - this being the central core of
this project); Dr. Laura Gonzalez-Lara (who trained me to use the clinical MRI scanner
and for those tricky quizzes you developed to test my knowledge); Dean Percy (for his
iv

expertise in gadolinium scans and for training me to prepare gas anesthesia connections);
Phil Gareau (for measuring tumour volumes for comparison with my results); Jonatan Snir
(for helping with the inundated animal scans over the summer and helping to troubleshoot
alongside with me problems with the mouse RF coils) and Roja Rohani (for aid in the use of
statistical software Graphpad Prism® version 5). I am truly grateful for all of your assistance
throughout the many phases of my research project.
I would also like to acknowledge, Christiane Mallett (for your help with poster layout and
formatting), Vasiliki Economopoulos (for burning files to dvds, and photographing mouse
brains), Dr. Amanda Hamilton, Dr. Gabrielle Siegers, and Sherri Couto (for your help
with miscellaneous aspects of my project). Your help is greatly appreciated.
To my loving, supportive and compassionate parents, who have inspired me through this
journey. You taught me the importance of perseverance, commitment and academic
inquisitiveness. You also instilled in me the benefits of gaining invaluable experiences. I
would also like to thank my brother, who constantly encouraged me to never give up, but to
meet each day with fresh determination in my academic journey. Also, a special thanks to all
my extended family and friends for their understanding and kind support.

v

Table of Contents
Certificate of Examination………….....................................................…...…...................ii
Abstract…………………………………………………………………………………...iii
Acknowledgments………………………………………………………...........................iv
Table of Contents…………………………………………………………………………vi
List of Tables………………………...................................................................................x
List of Figures………………………………………….....................................................xi
List of Abbreviations…………………………………………………………………....xiv
List of Symbol………………………………………………………………………….xvii
List of Appendices...…………………………………………………………………...xviii
Chapter 1………………………………………………………………………………....1
1 Introduction…………………………………………………………………………….1
1.1 Skin Cancer…………………………………………………………………….......1
1.1.1 Melanoma…………………………………………………………………….1
1.2 Metastasis…………………………………………………………………………..2
1.2.1 Mechanisms of Acquiring Blood Supply: Vessel Co-option vs.
Angiogenesis…………………………………………………………………..4
1.3 Melanoma Brain Metastases……………………………………………………….5
1.3.1 Incidence and Metastatic Propensity to the Brain …………………................5
1.3.2 Clinical Manifestation………………………………………………………...5
1.3.3 Clinical Treatment and Management…………………………………............6
1.4 The Blood-Brain Barrier (BBB) and Blood-Tumour Barrier (BTB) ……………...7
1.4.1 The Blood- Brain Barrier Structure…………………………..........................7
1.4.2 The Blood-Tumour Barrier………………………….......................................9
1.4.3 BBB and Chemotherapeutics………...………………………………...........10
vi

1.5 Animal Models of Melanoma Brain Metastases.…………………………………..10
1.5.1 Routes of Cell Injections……………………………………………………..10
1.5.2 Melanoma Mouse Models: Genetically Engineered, Xenotransplanted
and Syngeneic…………………………………………………………..........11
1.6 MRI Fundamentals.………………………………………………………………...13
1.6.1 MRI (Magnetic Resonance Imaging): Brief Introduction………..…..............13
1.7 Physics of MRI.……………………………………………………………………13
1.7.1 Basics of hydrogen atom behaviour…………………………………………. 13
1.7.2 MRI Gradients…………………………………………………......................16
1.7.3 Excitation and Relaxation…………………………………………………….16
1.8 Types of MRI Pulse Sequences ..........…...………………………………………..18
1.8.1 Spin Echo (SE) Pulse Sequence………………………………………………18
1.8.2 Gradient Echo (GRE) Pulse Sequence………………………………..............19
1.8.3 Balanced Steady-State Free Precession Pulse Sequence……..........................20
1.9 Contrast Mechanisms…………..……………………………………………..........22
1.10 Contrast Agents…………….……………………………………………………..23
1.10.1 T1 Shortening Agents……………………………………………................23
1.10.2 T2 Shortening Agents……………………………........................................24
1.11 MRI of Human Brain Metastases……………………………...…………….........25
1.11.1 MRI Sequences used in Detection of Human Brain
Metastases…………………………………………………………………...25
1.11.2 MRI Appearance of Melanoma Brain Metastases………………………….26
1.12 MRI of Brain Metastases in Animal Models……....………………………...........27
1.13 Thesis Overview and Objectives…………………………………………………..29
1.14 References……….……..…………………………………………………….........30
Chapter 2………………………………………………………………………………..40
vii

2 In vivo assessment of melanoma brain metastases using longitudinal MRI.…………40
2.1 Introduction……………………………………………………………………….41
2.2 Materials and Methods……………………………………………………............43
2.2.1 Experimental Groups……………………………………………………… 43
2.2.2 Cell culture and Cell Viability Assays……………………………………...43
2.2.3 Animal Model…………………….………………………………………...44
2.2.4 Imaging……………………………………………………………………..44
2.2.5 Image Analysis…………….………………………………………………..46
2.2.6 Histology and Microscopy………………………………………………….47
2.2.7 Statistical Analyses…………………………………………………………48
2.3 Results……………………………………………………………………………..49
2.3.1 Cell Labeling.……………………………………………………………….49
2.3.2 Imaging………………………………………………………………..........50
2.3.3 Longitudinal MRI…………………….…………………………………….57
2.4 Discussion…………...….……………………………………………………........70
2.5 References…………………………………………………………………............77
Chapter 3………………………………………………………………………………..84
3 Study Implications and Future Directions……………………………………………..84
3.1 Summary of Key Findings…………………………………………………..........84
3.1.1 Characterized Model of Melanoma Brain Metastasis using MRI.…….……84
3.1.2 Longitudinal Magnetic Resonance Imaging Studies: Early Detection
of Melanoma Brain Metastases using bSSFP…………….…………………85
3.1.3 Longitudinal Magnetic Resonance Imaging Studies: Variability in
Enhancement and Patterns of Enhancement………………………………...85
3.1.4 Longitudinal Magnetic Resonance Imaging Studies: Volume,
Location and Age of Enhancing and Nonenhancing Brain
viii

Metastases…………………………………………………………………..85
3.1.5 Histology: Ex vivo Permeability vs. In vivo Enhancement.…….…………..86
3.2 Biological Explanations of Metastasis Enhancement....……………………………86
3.2.1 BTB Modulation by VEGF-A……………………………..…….………….86
3.2.2 Alteration in Structure of the BBB….……………………..…….………….87
3.2.3 Enzymatic Activation and Cell-Cell Communication………………………87
3.3 Impact of Key Findings……………………………………………………………88
3.4 Study Limitations………………………………………………………………….89
3.5 Future Directions…………………………………………………………………..90
3.5.1 Histological and Immunohistochemical Characterization of Enhancing
and Nonenhancing Melanoma Brain Metastases……………………………90
3.5.2 Testing Therapeutic Efficacy using Clinically Relevant Model.……………91
3.5.3 Translation of the bSSFP Pulse Sequence for Brain Metastasis
Detection in the Clinic………………………………………………………91
3.5.4 Future MRI Studies for Melanoma Brain Metastases….…………………...92
3.6 References………………………………………………………………………....93
Appendices...…………………………………………………………………….............96
Curriculum Vitae......…………………………………………………………………...109

ix

List of Tables

Chapter 1:
Table 1.11.2. Stages of hemorrhage with accompanying changes in T1 and T2 signal
intensities (SI) of blood degradation products.........…………………………………………26

Chapter 2:
Table 2.3.1. Number of enhancing melanoma brain metastases over time………………….61

x

List of Figures
Chapter 1:
Figure 1.1.1. Diagram of skin anatomy and types of skin cancers including
melanoma……………………………………………………………………………………...2
Figure 1.2.1. The metastatic cascade...………………………………………………………..3
Figure 1.3.1. Diagram of human brain meninges...……..…………………………………….6
Figure 1.4.1. Cells associated with the BBB…...…………………………………………......8
Figure 1.7.1. Vector components of the net magnetization vector M0.……...………………15
Figure 1.7.3. T1 recovery curve.………..……………………………………………………17
Figure 1.8.1. Diagram of spin echo pulse sequence...……………………………………….19
Figure 1.8.3. Diagram of the bSSFP pulse sequence.....……………………………………..21
Figure 1.10.1. T1 recovery curve pre and post Gd-DTPA administration....……………..... 24

Chapter 2:
Figure 2.3.1. Perls Prussian blue staining of iron-labeled and unlabeled human melanoma
A2058 cultured cells…………………………………………………………………………49
Figure 2.3.2. Cell proliferation assay………………………………………………………..50
Figure 2.3.3. bSSFP image of a mouse brain day 1 post cell injection...……………………51
Figure 2.3.4. bSSFP images showing the appearance and spatial distribution of melanoma
metastases in a representative mouse brain………………………………………………….52

xi

Figure 2.3.5. bSSFP image of a melanoma meningeal metastasis in a mouse
brain…………………………………………………..……………………………………...53
Figure 2.3.6. Numbers of melanoma brain metastasis after 50,000 cells
injected..………………………………………………………..…………………………….54
Figure 2.3.7. Mean number of meningeal and parenchymal melanoma brain
metastasis.....………………………………………………..……………………………….55
Figure 2.3.8. MRI and H&E histology for A2058 melanoma meningeal brain
metastases………………………………..…………………………………………………..56
Figure 2.3.9. MRI and H&E histology for A2058 melanoma parenchymal brain
metastases……....…………………………..………………………………………………..57
Figure 2.3.10. bSSFP and T1wSE post Gd-DTPA images of brain metastases……………..59
Figure 2.3.11. Heterogeneity in enhancement for A2058 melanoma brain
metastases………………………………………………………………………………........60
Figure 2.3.12. bSSFP images show development of a hemorrhagic metastasis and
nonhemorrhagic metastases…………………………………………………………..……...63
Figure 2.3.13. Volumes of enhancing and nonenhancing of A2058 melanoma brain
metastases at each time point……..………………………………………………………….64
Figure 2.3.14. Representative bSSFP images comparing volumes for nonenhancing and
enhancing melanoma brain metastases from the same mouse……………………………….65
Figure 2.3.15. Differences in patterns of enhancement over time for A2058 melanoma brain
metastases………………………………………………………..…………………………..66
Figure 2.3.16. Representative T1wSE post Gd-DTPA and bSSFP images of an enhancing
metastasis with corresponding Dextran and H&E histology……….………………………..67
Figure 2.3.17. Representative T1wSE post Gd-DTPA and bSSFP images of a nonenhancing
metastasis with corresponding Dextran and H&E histology…...............................................68
xii

Figure 2.3.18. Representative T1wSE post Gd-DTPA and bSSFP images of an enhancing and
nonenhancing metastasis with corresponding H&E histology .……………………………..69

xiii

List of Abbreviations

3D

Three-dimensional

5-FC

5-Fluorocytosine

ACVS

Animal care and veterinary services

AIB

Alpha-aminoisobutyric acid

AJ

Adheren junction

ATCC

American type culture collection

BBB

Blood-brain barrier

b-FGF

basic fibroblast growth factor

BLI

Bioluminescence imaging

bSSFP

Balanced steady-state free precession

BTB

Blood-tumour barrier

CD

Cytosine deaminase

CE

Contrast enhancement

CNS

Central nervous system

CSF

Cerebral spinal fluid

Da

Dalton

DCE

Dynamic contrast enhancement

Deoxy-Hb

Deoxyhemoglobin

DMEM

Dulbecco’s modified eagle medium

ECM

Extracellular matrix

FA

Flip angle

3+

Fe

Iron (+3) ion

FBS

Fetal bovine serum

FTM

Fotemustine

FOV

Field of view

FUS

Focused ultrasound

Gd

Gadolinium

3+

Gd

Gadolinium (+3) ion

Gd-DTPA

Gadopentatic acid or Gadopentetate dimeglumine

GE

General electric

GEM

Genetic engineered mouse

GFAP

Glial fibrillary acidic protein
xiv

GLUT-1

Glucose transporter-1

GRE

Gradient echo

H&E

Hematoxylin and Eosin

HBSS

Hank’s balanced salt solution

Hb

Hemoglobin

IC

Intracardiac

ICA

Intracarotid

IP

Intraperitoneal

IL-8

Interleukin 8

IV

Intravenous

kDa

Kilo dalton

Met-Hb

Methemoglobin

MHz

Megahertz

MPIO

Micron-sized iron oxide

NEX

Number of excitations

NSPCs

Neural stem/Progenitor cells

MRI

Magnetic resonance imaging

O.C.T

Optimal Cutting Temperature

PBCA

Poly (n-butyl cyanoacrylate)

PD

Proton density

PC

Phase cycles

PEG

Polyethylene glycol

PPB

Perls Prussian blue

PFA

Paraformaldehyde

RBC

Red blood cell

rBW

Receiver bandwidth

RF

Radiofrequency

SD

Standard deviation

SE

Spin echo

SI

Signal intensity

SNR

Signal- to –noise ratio

SPIO

Superparamagnetic iron oxide

T

Tesla

STAT-3

Signal transducer and activator of transcription 3

TE

Echo time
xv

TGF-β

Transforming growth factor beta

TJ

Tight junction

TR

Repetition time

T1w

T1 weighted

T1wSE

T1 weighted spin echo

T2w

T2 weighted

T2*w GRE

T2 star weighted gradient echo

T2w SE

T2 weighted spin echo

TMZ

Temozolomide

USPIO

Ultra small superparamagnetic iron oxide

UV

Ultraviolet

VEGF

Vascular endothelial growth factor

WBRT

Whole brain radiotherapy

xvi

List of Symbols

B0

External magnetic field

Gs

Slice selection gradient

Gp

Phase encoding gradient

Gf

Frequency encoding gradient



Planck’s constant

I

Spin angular momentum

J

Angular momentum

κ

Boltzmann constant

M0

Net magnetization vector

Mz

Longitudinal magnetization vector

Mxy

Transverse magnetization vector

ρ

Proton density

T(°C)

Temperature

µ

Magnetic moment

ω0

Larmor frequency

γ

Gyromagnetic ratio

Β

xvii

List of Appendices

Appendix A: Animal use Protocol …………………………………………………………96
Appendix B: Inter and intra observer metastasis volume measurements……………………97
Appendix C: Total metastatic burden ……………………………………………………...100
Appendix D: Total, mean metastasis number and mean volumes for meningeal and
parenchymal brain metastases………………………………………………………………101
Appendix E: Melanoma brain metastases hemorrhage……………………………………..102
Appendix F: Pilot study using USPIO (Molday) for tumour vasculature analysis………....103
Appendix G: Melanin images………………………………………………………………105
Appendix H: License and permission usage………………………………………………..106

xviii

“The significant problems we have cannot be solved at the same level of thinking
with which we created them”
-Albert Einstein

xix

1

Chapter 1

1

Introduction

1.1 Skin Cancer
1.1.1 Melanoma
Melanoma is one of three types of skin cancers, it is the second most prevalent cancer to
affect young adults ranging in age from 15-29 years of age (1-3). There are three types of
skin cancers: basal cell carcinoma, which is the most frequent, squamous cell carcinoma and
malignant melanoma. Malignant melanoma is the most dangerous form of skin cancer and it
is the leading cause of death among skin cancers (4,5). Melanoma is a malignancy of
melanocytes, the pigment producing cells of the skin. Melanocytes produce melanin, which
is associated with skin colour but also acts to block ultraviolet (UV) radiation thereby
protecting the skin from deoxyribonucleic acid damage (6). Melanomas can appear as black,
brown, red, white, pink, purple or blue. Warning signs of melanoma can be detected using
the ABCDE method: A=asymmetry in a mole, B=borders are uneven (irregular), C= colour
variation in a mole, D= diameter of a mole is larger than 6mm, E=evolving, any changes in a
mole such as size, colour, or new behaviour i.e. bleeding, itching (4). Common risk factors
associated with melanoma include: exposure to UV radiation (i.e. sun, tanning beds), lightcoloured skin, hair and eyes, familial and personal history of skin cancer, sunburns, large
number of moles (>50), and atypical moles (6). Figure 1.1.1 shows the skin anatomy, types
of skin cancers and the location of melanocytes (7). The skin is divided into two upper layers
known as the epidermis and dermis and an underlying third layer known as the hypodermis
or subcutis (6). Melanocytes are located in the deepest basal layer of the epidermis (6).
Malignant melanoma is deadly since it is capable of metastasizing rapidly to other organs
such as liver, lung and lymph nodes producing visceral metastasis, and compared to all
primary tumours it has the highest propensity to metastasize to the brain (8,9).
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Figure 1.1.1 Diagram of skin anatomy and types of skin cancers including melanoma.
The two main layers of the skin include: epidermis and dermis. Each type of skin cancer is
derived from three different cell types within the skin epidermis: squamous cells, basal cells
and melanocytes. Melanocytes are located at the epidermal and dermal junction of the skin;
basal layer of the skin epidermis. Compared to basal and squamous cancers melanoma
invades deep into the dermal layer of skin. Source: Reprinted from the MayoClinic.com
Image “Where skin cancer develops” (http://www.mayoclinic.com/health/medical/IM02400).
©Mayo Foundation for Medical Education and Research. All rights reserved. With
permission for re-usage from Mayo Clinic. (7)

1.2 Metastasis
A common problem associated with cancer is metastasis, whereby cells from a primary
tumour spread to other organs in the body (10). Metastasis is the leading cause of death
among cancer patients (10). Metastasis occurs by one of two routes: hematogenous or
lymphatic dissemination (11,12). Hematogenous dissemination refers to cellular spread via
the blood circulatory system whereas lymphatic dissemination refers to cells travelling
through the lymphatic vessels. In order for a cancer cell to successfully grow elsewhere in the
body it must go through a series of steps that is known as the metastatic cascade (13,14),
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figure 1.2 shows a diagram of the metastatic cascade. To initiate metastasis, 1) tumour cells
must first breakdown the extracellular matrix (ECM), of the surrounding tissue thereby
enabling the cells to 2) intravasate into nearby blood or lymphatic vessels. 3) After
intravasation, the cells can then travel to distant organ sites. 4) Once the cancer cells arrive
at a target organ site, 5) they must arrest by binding to vascular endothelial cells and then 6)
extravasate from the blood vessels into the organ parenchyma. Not every cell that escapes
from the primary tumour completes all steps of the metastatic process, this may lead to
absence in metastasis development, and thus metastasis is an inefficient process. (15-18).

Figure 1.2. The metastatic cascade. (a) The metastatic cascade comprises a series of steps
that a tumour cell must undergo to disseminate to a secondary site.
(http://www.nature.com/nrc/index.html). Reprinted by permission from MacMillan
Publishers Ltd: Nature Reviews Cancer Chambers et al. 2:563-572 copyright© 2002 August
Nature Publishing Group. (14)

Metastasis to the brain is the most feared complication of systemic cancer (19) because it is
an incurable and a debilitating disease. It is estimated that 20-40% of cancer patients will
develop brain metastases (8). Brain metastases are also the most prevalent type of intracranial
tumour (8,20). Three common primary cancers that result in brain metastasis are lung cancer,
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breast cancer and melanoma (8, 21, 22) all of which result in dismal prognosis as exemplified
by short median survivals.

1.2.1 Mechanisms of Acquiring Blood Supply: Vessel Co-option vs. Angiogenesis
Primary tumour cells that successfully extravasate have shown altered mechanisms of target
tissue invasion. The two most commonly reported mechanisms of acquiring blood supply are
vessel co-option and angiogenesis (23-26). Angiogenesis is the development or formation of
new blood vessels (27). This process is mediated by signaling molecules such as vascular
endothelial growth factor (VEGF). VEGF is the most common and potent angiogenic factor
described in the literature and has been shown to function in the vasodilation of blood
vessels, the induction of vascular permeability, and the migration of endothelial cells to form
new blood vessel structures (28-31). Previous studies of cancer growth have shown that
angiogenesis is a requirement for tumor growth and proliferation (32).

In the brain, however, the large vascular supply often permits metastatic tumour growth
without the promotion of angiogenesis (33). Melanoma and breast cancer brain metastases
rely on vessel co-option whereby tumour cells use pre-existing blood vessels as their blood
supply for growth and proliferation (34). Confocal microscopy analysis of melanoma and
breast cancer co-opted vessels revealed that these cells were elongated in a perivascular
position or pericyte-like position along cerebral blood vessels (34,35). Kienast et al. used in
vivo multiphoton laser scanning microscopy to demonstrate that two melanoma cell lines
(MDA-MB-235 and A2058) were capable of invading and proliferating within the brain by
co-opting cerebral microvessels. In addition, this study showed that after extravasation into
the brain tissue, lung cancer cells (PC14-PE6) proliferated into small clusters that were in
close proximity to each another. These clusters eventually fused together to form large
lesions where angiogenesis was induced (35).
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1.3 Melanoma Brain Metastases
1.3.1 Incidence and Metastatic Propensity to the Brain
The reported clinical incidence of melanoma brain metastasis is 6-43% (36), although
autopsy reports have shown higher incidences of 75 -90% (22,37). Melanoma is the third
most common cancer to cause brain metastasis (19,22) after lung and breast cancer; however,
melanoma has the highest propensity to metastasize to the brain compared to all other
primary tumours (9,38). Brain metastasis is most often detected within 1 year of primary
cancer diagnosis for melanoma (39).

1.3.2 Clinical Manifestation
Clinical cases of melanoma brain metastasis often present with multiple lesions that are
multifocal (40). These can occur anywhere in the central nervous system (CNS) and may be
associated with leptomeningeal spread (40). Patients can also present with single lesions but
these are less common (41,42). Figure. 1.3.2 shows the meningeal layers of the human brain.
The meninges are membranous linings consisting of the dura, arachnoid and pia (43) that
cover the brain and serve to protect it from injury, they also house blood vessels and cerebral
spinal fluid (CSF) (44,45). CSF is secreted in the subarachnoid space between the arachnoid
and pia mater (45). Other manifestations of melanoma brain metastases include hemorrhage
(46), hydrocephalus (abnormal accumulation of CSF in brain ventricles), and mass effects
leading to increased fluid pressure (19).

The pattern of seeding for tumour cells in patients with melanoma brain metastasis is as
follows: parenchymal (cortex) 49 %, leptomeningeal (arachnoid and pia) 22%, and dural 32
% (47,48). An autopsy study reviewed by de la Monte et al. showed that the number of CNS
cases with metastases due to melanoma was 88% in the cortex, 63% in the meninges and
24% in the dura (49).
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Figure 1.3.2. Diagram of human brain meninges. A protective membrane layer known as
the meninges covers the brain. There are three meningeal layers: the most outer layer closest
to the human skull is known as the dura mater, the second layer is the arachnoid mater, the
third layer and is furthest away from the skull is the pia mater. In between the arachnoid and
pia mater is the subarachnoid space that contains CSF and blood vessels. Source: Reprinted
from
the
MayoClinic.com
Image
“Meningitis”
(http://www.mayoclinic.com/health/medical/IM00113). ©Mayo Foundation for Medical
Education and Research. All rights reserved. With permission for reusage from Mayo Clinic.
(44)

The number of melanoma brain metastases detected in humans typically ranges between 1-10
metastases (50,51). Previous studies have shown a correlation between the number of brain
metastases and patient survival (19,41,42,52).

1.3.3 Clinical Treatment and Management
Current brain metastases treatments are often palliative and ultimately aim to stabilize
neurologic symptoms (8). Potential therapies include radiosurgery, surgery, whole brain
radiotherapy (WBRT), corticosteroid treatment (symptomatic treatment to reduce edema) and
chemotherapy (8,20,53,54). The number of metastases is an important factor for determining
the course of treatment (37,52). Surgery is usually reserved for patients who have a single
lesion that is surgically accessible (8). For multiple lesions WBRT is used (9). Despite
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treatment efforts, the general prognosis for patients with multiple metastases is poor (52).
There is still debate about whether it is the number of metastatic lesions or the lesion volume
that impacts patient prognosis the most (52). Melanoma brain metastases are typically
radioresistant (8).

1.4

The Blood- Brain Barrier (BBB) and Blood –Tumour

Barrier (BTB)
1.4.1 The Blood-Brain Barrier Structure
The BBB functions to protect the brain from foreign materials such as microorganisms and
toxic substances (55,56). The core component of the BBB is the endothelium of the brain
microcirculation, which is supported by specialized cells such as astrocyte, pericytes,
microglia and neurons (55,57).

These cells line the endothelial cells of the cerebral

vasculature and together they function as a unit to stabilize blood vessel walls and maintain
BBB integrity (56). Figure 1.4.1 shows the structure and cell composition of the BBB.
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Figure 1.4.1 Cells associated with the BBB. This figure illustrates the specialized cells
associated with the BBB, which include pericyte, astrocytic foot processes, neurons, and
microglia. These cells are closely associated with the cerebral endothelial cells and together
form a structural barrier. Tight junctions connect the cerebral endothelial cells. BL1 and BL2
are two different extracellular matrices of the basal lamina (BL); BL1 represents a distinctive
extracellular matrix in association with endothelial cells and pericytes, BL2 represents a
different extracellular matrix in association with astrocytic foot processes. Axonal terminals
of neurons (in close proximity to smooth muscles) contain vasoactive neurotransmitters and
peptides that control cerebral blood. Reprinted from Neurobiology of Disease, volume 37, N
Joan Abbott, Adjanie A.K. Patabendige, Diana E.M. Dolman, Siti R Yusof, David J.Begley,
Structure and function of the blood-brain barrier, pages 13-25, Copyright © 2009, with
permission from Elsevier. (56)

Other structural components of the BBB include tight junctions (TJ) and adheren junctions
(AJ). These junctions are responsible for controlling the paracellular permeability of the BBB
endothelium (58,59). The TJ, function in adjoining adjacent endothelial cells forming a seal
(55). AJ are responsible for the development and maintenance of TJ and also form
connections between endothelial cells (55, 58).

The BBB is a selective barrier. Generally small molecules <400-600 daltons (Da), neutral
and lipophilic, are more likely to permeate the BBB (55,60). Molecules that are essential for
brain function that can permeate across the BBB include ions, blood gases O2, and CO2 that
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enter via passive permeability (59); glucose and amino acids which enter via solute
transporters; proteins and peptides which enter via transcytosis through receptor mediated
mechanism (59).

Disruption of the BBB is often indicative of the presence a pathological condition (56), thus
changes in permeability can be seen as an early indicator of an abnormality within the brain.
Dextran is commonly used as an ex vivo tracer to monitor BBB integrity, it ranges in size
from 3 kilo Dalton (kDa) - 70kDa (61). It is also important to note that permeability is a
dynamic process that coincides with altered demands for nutrients, protection from foreign
substances, local repair processes and other requirements that might be necessary for proper
function (56). Although the BBB acts to protect the brain from foreign agents that are
detrimental to brain function (62), some metastatic cells are able to penetrate the BBB and
invade the brain parenchyma (47).

1.4.2 The Blood-Tumour Barrier
The BTB refers to the interface between tumours and tumour-associated blood vessels. Blood
vessels in regions of the BTB can have altered barrier integrity

(63) possibly due to

macromolecules secreted by tumour cells such as VEGF-A and basic fibroblast growth factor
(b-FGF) (64). Tumour-associated blood vessels have been shown to exhibit features more
similar to systemic blood vessels rather than their cerebral counterparts (63). In addition,
tumour-associated blood vessels are abnormal in that they exhibit convoluted patterns of
branching, tortuosity (meaning that they twist and bend unusually), and an altered propensity
for leakage (65) compared to the blood vessels of the BBB in the surrounding brain
parenchyma tissue (66). Blood vessels of the BTB have also been shown to be co-opted (35)
and may also demonstrate sprouting angiogenesis (67).
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1.4.3 BBB and Chemotherapeutics
Chemotherapeutic agents range in size from 600 – 1400 Da (63). Most chemotherapeutics are
not able to cross the BBB and the BTB and subsequently have had limited efficacy in the
treatment of brain metastases. In metastatic melanoma, both systemic and brain metastases
typically exhibit an overall poor response rate to systemic chemotherapy (68). Some
chemotherapeutics agents, such as temozolomize (TMZ) and nitrosourea fotemustine (FTM),
have been shown to cross the BBB and treat melanoma brain metastases. However, the use
of these drugs as single agents showed a modest tumor response rate in the case of
nitrosourea FTM and a low tumor response rate for TMZ (69-71). TMZ and nitrosourea
FTM administered in combination with other therapeutic agents, e.g. WBRT or thalidomide
(anti-angiogenesis agent), has also shown limited success; with a median survival rate
between 2-6 months (21,71-73). There is an urgent need for new, more effective therapies
against brain metastasis (39).

1.5 Animal Models of Melanoma Brain Metastases
1.5.1 Routes of Cell Injections
Animal models of melanoma brain metastasis that mimic hematogenous spread can be
derived by intracardiac (IC) or intracarotid (ICA) cell injection. Less commonly used cell
injection

routes

include:

intravenous

(IV)

(injection

of

cells

into

a

vein),

intracerebral/intracranial (direct implantation of cell into the cerebral cortex) and intrathecal
(injection of cells into the subarachnoid space) (74). The intracarotid cell injection method
has been the most extensively used for producing blood-borne experimental brain metastases,
however, a few previous studies have successfully used the intracardiac cell injection method
for the production of brain metastases (34,61,75-81). Although intravenous injections are
based on cells injected into the venous circulation they are not suitable for brain metastasis
production

since

the

first

capillary

bed

encountered

by

cells

is

the

lungs.

Intracerebral/intracranial and intrathecal cell injection routes are not representative of
hematogenous spread since tumour cells are not injected into the circulatory system.
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IC injections involve injecting cells into the left ventricle of the beating animal heart. An
advantage of using the IC method is that it is relatively simple in terms of cell delivery (74).
Meanwhile, ICA involves injecting cells into the internal carotid artery. This method of cell
injection eliminates cell distribution to other organ sites however it requires extensive skills
in microsurgery (74) and typically only one side of the brain shows presence of metastases.

1.5.2 Melanoma Mouse Models: Genetically Engineered, Xenotranplanted, and Syngeneic
Animal models of melanoma brain metastasis commonly use human cells that are
transplanted into athymic nude (nu/nu) mice. Tumours are able to grow in nude mice because
they lack a thymus thereby making them incapable of producing mature T cells that are
involved in the adaptive immune system and are responsible for the recognition of foreign
antigens. Human tumours heterotransplanted into immunodeficient mice are also able to
retain their morphologic and biochemical characteristics (82,83).

Most models of brain metastases can be classified as either spontaneous or experimental (84).
Three types of mouse models for melanoma have been used experimentally: genetically
engineered models (GEM) are a type of spontaneous model, xenotransplantation models and
syngeneic transplantation model (85) are two different types of experimental metastasis
models. Xenotransplantation refers to orthotopic implantation of cells from one species into
another (i.e. human primary or secondary tissue into a mouse model) (13) whereas syngeneic
transplantation refers to implantation of cells from the same species origin. Each of these
models serves a different purpose depending on the type of experimental question being
asked. For instance, GEM such as BRAFV600E Cdkn2a +/- background (86) are useful for
studying the early metastatic progression such as the initiation of tumorigenesis; genetic
changes in melanocytes turns them into malignant melamoma cells. A disadvantage in this
type of model is that GEM have shown limited capability of producing metastasis (85,87).
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Xenotransplantation models are useful for looking at metastatic behaviour. An example of a
xenotransplantation model is the A375-SM metastatic melanoma lymph node cell line
injected into nude mice (47,74,82,88). Syngeneic models are useful for monitoring immune
reactions in response to allograft cells that were injected e.g. a common syngeneic model
used in melanoma research is the injection of B16 melanoma cells into C57BL/6 mice
(74,89).

Most experimental metastasis models inject tumour cells directly into the circulation (84),
thereby bypassing the early stages of the metastatic cascade (13). In this method emphasis is
placed on the later stages of metastasis, which includes cell arrest in capillary beds,
extravasation, invasion, angiogenesis or vessel co-option and proliferation. Spontaneous
metastatic models encompass the entire metastatic cascade from early stages (primary site) to
late stages (secondary site) (13). The site of inoculation is where a primary tumour is
established and the animals are monitored for the formation of visceral metastases (84). A
few spontaneous models of melanoma have been reported that demonstrate metastasis to the
brain (90,91). For instance Alterman et al. have shown that that B16 clones G3.5 and G3.12
were capable of producing spontaneous metastasis to the brain and Cruz Munoz et al. have
demonstrated that the metastatic melanoma cell line 113/6-4L derived from the WM239A
human melanoma parental cell line also showed spontaneous metastasis to the brain.
Spontaneous models of melanoma brain metastasis are rare and less reproducible; few cell
lines have been reported that are capable of spontaneously metastasizing to the CNS from a
primary tumour (92). For this reason experimental metastasis models are more commonly
used compared to spontaneous models to study experimental brain metastasis.
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1.6 MRI Fundamentals
1.6.1 MRI (Magnetic Resonance Imaging): Brief Introduction
MRI is a widely used noninvasive imaging modality. Advantages of MRI include excellent
soft-tissue contrast, high sensitivity, high-resolution and no ionizing radiation source (93).
Magnetism or magnetic fields is the core foundation for imaging in MRI (93). The principle
of MRI stems from the inherent properties of protons or hydrogen atoms (1H nuclei) (93).
The human body is composed of 75% to 80% water and fat (93) providing a large pool of
protons that enables MR imaging.

1.7 Physics of MRI
1.7.1 Basics of hydrogen atom behaviour
The signal acquired from MRI is based on nuclear magnetic resonance (NMR). The nucleus
of hydrogen atoms consists of one positively charged proton. The hydrogen atom possesses
an odd number of protons, thus it will exhibit nuclear spin, which is a quantum mechanical
property as well as spin angular momentum. A moving charged particle (e.g. a proton) can
induce a magnetic field. The larger the magnitude of the charge or speed, the greater the
magnetic field induced. The magnetic field produced is known as the magnetic moment (µ),
which is directly proportional to angular momentum (93) (refer to equation 1.7a). The
magnetic moment is a vector quantity (94).

µ= γJ=γΙ (93) (Equation 1.7a)

Where µ is the magnetic moment, γ is the gyromagnetic ratio, J is the angular momentum, 
is Planck’s constant divided by 2π and Ι is the spin angular momentum number equaled to 
for protons (93).
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In the absence of an external magnetic field, hydrogen atoms spin randomly where the vector
sum of the magnetic moments is zero. In the presence of an external magnetic field, the spins
of protons are described as being quantized (distributed amongst different energy levels), in
the case of the hydrogen atom two energy states exist. When protons are placed in an
external magnetic field some spins are slightly aligned with the magnetic field (parallel
direction); lower energy state and some spins are slightly aligned in the opposite direction
(anti-parallel direction) of the magnetic field; higher energy state. Parallel and anti-parallel
spins will cancel out but a small subset or excess of spins will be aligned with the magnetic
field producing a net magnetization vector. Figure 1.7.1 shows the vector components of the
net magnetization vector, which are Mz and Mxy (96).

As you increase in magnetic field strength, the magnitude in energy difference increases for
energy states. More spins will be slightly aligned with the magnetic field. In reality the spins
of protons switch back and forth from the two energy states and the ratio of protons that are
parallel and anti-parallel will depend on the magnetic field strength and temperature that is
inversely proportional to the ratio of parallel and anti-parallel spins of protons (refer to
equation 1.7b).

M0= ργ22Β0 (93) (Equation 1.7b)
4κ T (°C)
Β

Where M0 is the net magnetization, ρ is the proton density, Β0 is the magnetic field strength,
κ is the Boltzmann constant 1.38 x10-23 JK-1, T is the temperature (body temperature 37°C)
Β

(93). By conducting experimental measurements (e.g. collecting MRI signal) we are able to
know the probability of distribution of spins among the energy levels.
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Figure 1.7.1 Vector components of the net magnetization vector M0. M0 is the net
magnetization vector which is the sum of the Mxy and Mz vector components. Mxy is the
vector component in the xy transverse plane and Mz is the vector component along the Z axis
longitudinal plane.

In the presence of a magnetic field, the protons resonate, or precess, at a given frequency, this
frequency is known as the Larmor frequency and is defined by the following equation:

ω0 = B0 x γ (91)

(Equation 1.7c)

Where ω0 is the Larmor frequency, B0 is the magnetic field strength and γ is the
gyromagnetic ratio (γ), which is a constant value for a particular nucleus. The units of γ are
megahertz (MHz) per Tesla (T). The Larmor frequency at 3T for proton nuclei is 127.71
MHz, where B0 = 3T and the gyromagnetic ratio for protons is (γ/2π) = 42.57 MHz T-1.
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1.7.2 MRI Gradients
Gradient coils are used in MRI to create short-term spatial variations in the magnetic field
strength (93). Gradient coils create linear gradients along all three axes x, y, and z (Gx, Gy
and Gz) (93) during imaging. The Larmor frequency of protons changes along the linear
gradients because each proton senses a different magnetic field strength (93,96).

Slice selection gradients (Gs) select a region of the sample to be imaged. This is the target
slice for the radiofrequency (RF) pulse (composed of an electromagnetic wave) application
(93,96). Phase encode gradients (Gp) assign a different phase (position/direction) to protons
in the selected image slice (93). Frequency encoding gradients (Gf) assign a different
frequency to protons in the selected image slice in one direction. The information of each
frequency and phase encoding from the image is stored in an image matrix consisting of rows
and columns in which each box in the matrix is known as a voxel or voxel volume. Each
voxel has a unique frequency and phase code. The voxels are assigned a unique number and
are stored as raw data in k-space (93). A mathematical program known as Fourier transform
is used to convert the raw data stored in k-space into image space where the image is created
(93).

1.7.3 Excitation and Relaxation
Protons are excited through absorption of energy from an RF pulse that corresponds to the
Larmor frequency, causing tipping of protons into the transverse (xy) plane (93,94). After the
RF pulse is removed, protons relax back to their resting state (lower energy) by three
different mechanisms (93,94): T1 recovery, T2 relaxation and T2* relaxation (93,94).

T1 recovery, also known as spin-lattice relaxation or longitudinal relaxation (93,94), is where
protons release energy into the surrounding lattice or tissue environment in order to return to
their resting state (93, 96). During T1 recovery the Mz vector component grows in size along
the z-axis as it returns back to equilibrium. This relaxation is represented by an exponential
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curve described as a T1 recovery curve where equilibrium of protons is reached when 63% of
the vector has been recovered, this is the T1 value or time. (93,94). Each tissue has a
different T1. Figure 1.7.3 shows a diagram illustrating T1 recovery of protons.

Figure 1.7.3 T1 recovery curve. When protons relax back to equilibrium, T1 is defined as
the time reached where 63% of the original signal has recovered.

T2 relaxation, also known as spin-spin relaxation or transverse relaxation is defined by
protons sensing different magnetic field strengths caused by the dephasing interactions from
neighbouring protons (93,96). This results in protons precessing at various frequencies and
eventually become out of phase. During this dephasing, the magnetization vector Mxy
decreases in magnitude resulting in signal decay or T2 decay (93,94). T2 decay is represented
by an exponential decay curve. The time it takes for the signal to reach 36% of the original
signal is referred to as T2 (93,94). Each tissue has a unique T2 value (94). Aside from
inherent dephasing properties, protons are also sensitive to magnetic field inhomogeneities
that can be caused by air and metal objects. In the presence of random T2 effects (loss of
phase) as well as field inhomogeneities (non-homogenous magnetic field strength), protons
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decay more rapidly. This is referred to as T2* decay. This phenomenon is represented by an
exponential decay that represents signal loss.

1.8 Types of MRI Pulse Sequences
In MRI two types of fundamental pulse sequences are used: spin echo (SE) and gradient echo
(GRE). Various MRI pulse sequences are classified in either the SE or GRE pulse sequence
families (93). The pulse sequences utilized in this thesis are a T1 weighted SE (T1wSE)
sequence and the balanced steady-state free precession (bSSFP) sequence, which is a GRE
pulse sequence.

1.8.1 Spin Echo (SE) Pulse Sequence
The SE sequence uses of an excitation pulse of 90° to tip protons into the transverse plane. At
TE/2, a 180° refocusing pulse is used to bring protons back into phase, and at a time TE the
in-phase protons produce an echo (signal acquired) (94). Three types of gradients are used
during image acquisition for SE pulse sequence: The slice selection gradient is turned on
when the excitation pulse is released, the phase encode gradient encodes different phases for
protons. The frequency or readout gradient is turned on at the time the echo is acquired.
Figure 1.8.1 shows the diagram of a spin echo pulse sequence.
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Figure 1.8.1 Diagram of spin echo pulse sequence. This pulse sequence has a 90°excitation
pulse and a 180° refocusing pulse. After applying the refocusing pulse, at a time TE an echo
(signal) is acquired. GSS = slice selection gradient, GPE = phase encoding gradient, GFE
=frequency encoding gradient, TR repetition time, TE echo time. Modified from (93).

1.8.2 Gradient Echo (GRE) Pulse Sequence
GRE sequences use flip angles that are less than 90°. Only one RF pulse is used, and instead
of using a refocusing pulse, out of phase protons are rephased through the application of a
negative gradient opposite in direction. When protons are in-phase an echo is generated
(93,94). Unlike SE sequences, GRE sequences are sensitive to inhomogeneities. GRE
sequences are faster and thus shorter scan times are produced (93).
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1.8.3 Balanced Steady-State Free Precession Pulse Sequence (b-SSFP):
The bSSFP pulse sequence is a member of the GRE pulse sequence family (93). In a bSSFP
pulse sequence the gradients are balanced to produce a signal that eventually remains in
‘steady state’. The net magnetization vector is in steady state because in between each TR
interval the balanced gradients refocus the signal to generate a single magnetization vector.
During each TR interval T1 and T2 relaxation is occurring but do not recover or decay fully
due to rephasing caused by balanced gradients, the resulting magnetization vector is used in
the next TR period and the process is repeated multiple times (97).

The contrast in bSSFP is related to T2/T1 (97). Figure 1.8.3 shows the bSSFP pulse sequence
diagram. bSSFP is regarded as a pulse sequence that produces the highest signal- to- noise
ratio (SNR) per unit time (98) because it is able to maintain a steady and refocused signal at
every TR cycle. An advantage of using bSSFP is that high resolution images can be
generated while maintaining a high SNR in reasonable scan times.
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Figure 1.8.3 Diagram of the bSSFP pulse sequence. In this pulse sequence, gradients are
balanced and signal is refocused at each TR cycle; producing a high SNR per unit time. S =
slice select gradient, P = phase encoding gradient, and R = frequency readout gradient.
Springer and European Radiology/, volume 13, year of publication 2003, page 2410, article
title: Principles and applications of balanced SSFP techniques, Authors: Klaus Scheffler and
Stefan Lehnhardt, figure 2, © Springer-Verlag 2003. With kind permission from Springer
Science and Business Media. (97)

Applications of bSSFP
Heart cine imaging is the major clinical application of bSSFP (97). bSSFP has also been used
in cardiac imaging and angiography for delineation of small structures (97). bSSFP has also
more recently been used to generate very high resolution images useful for the differentiation
between pineal cysts and pineal tumours (99),

bSSFP has been used in our research group for several studies involving cellular MRI
whereby cells are labeled and tracked post cell injection. bSSFP is sensitive to iron due to
inhomogeneities produced by the iron agent. bSSFP has been used to track and detect iron
labeled cells in various disease models such as prostate cancer, spinal cord injury, brain
metastasis (breast cancer) and brain cancer (glioma) detection, development and progression,
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dendritic cells in cancer immunotherapy, melanoma metastasis to lymph nodes, and multiple
sclerosis (80,81,100-106).

1.9 Contrast Mechanisms
Two key imaging parameters important for image contrast are repetition time (TR) and echo
time (TE) (96). The repetition time is defined as the time between excitations (94). The echo
time is the time from when the RF pulse is first applied to when the MRI signal is detected
(95). By adjusting the TR and TE, three common image contrasts can be generated in MRI
(96): T1 weighted (T1w), T2 weighted (T2w) and Proton Density weighted (PD) contrasts.

In T1w images, tissues with a long T1 time (e.g. fluids) appear dark and tissues with short T1
(e.g. fat) appear bright. T1w images are typically used to look at the anatomy and are known
as anatomy scans (93). For SE sequences T1w images are produced using a short TR and TE.
Typically a flip angle (FA) greater than 50° and short TE times are used to generate T1w
contrasts for GRE sequences (93).

In T2w images tissues with a long T2 (e.g. fluids) appear bright and tissues with a short T2
appear dark. Clinically T2w images are referred to as pathology scans since most pathologies
have associated edema, which appears very bright (93). T2w images are produced by using
long TR and TE for SE sequences and using FA smaller than 40° and long TE for GRE
sequences (93). PD images are based on the density of protons of water and fat in a volume
of tissue (94). PD images are produced using a long TR and a short TE for SE sequences and
using FA smaller than 40° and short TE for GRE sequences (93).

In bSSFP images tissues show T2/T1 contrast, e.g. grey and white matter show low softtissue contrast because the ratios of T2 and T1 are the same. Fats and water produce high
signal intensities (SI) in bSSFP. In the case of hemorrhage, shortening of T2 and T1 produce
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isointense and hyperintense signals. Shortening of T2 and T1 (the more predominant effect
due to the presence of extracellular methemoglobin (Met-Hb)) produces hyperintense signals,
and shortening of T2 (the more predominant effect due to the presence of superparamagnetic
particles such as hemosiderin) and T1 produces hypointense signals.

1.10 Contrast Agents
1.10.1 T1 Shortening Agents
Gadolinium contrast agents are paramagnetic (93,94) and referred to as T1 shortening agents
since they shorten T1 of tissues and post-contrast tissues appear bright (hyperintense) on
T1w images (93). Figure 1.10.1 shows T1 shortening (increase in T1 signal; hyperintense) of
T1 after administration of gadolinium contrast agent. In the case of brain metastases with
disrupted BTB, Gd-DTPA is able to leak into the metastases and cause T1 shortening of
neighbouring protons within the metastasis. These contrast agents are used extensively to
monitor or measure the BBB and/or BTB integrity (63). The most widely used gadolinum
contrast agent in MRI clinical imaging is gadolinium-diethylenetriaminepentaacetic acid or
gadopentetate dimeglumine (Gd-DTPA) also known as Magnevist. Gd-DTPA is composed
of a metal ion Gd3+ that is chelated by the pentaacetic acid ring. This agent has 7 unpaired
electrons (94), which causes gadolinium to be paramagnetic. Gadolinium agents used to
monitor BBB integrity range in size from 590 to 950 Da. (63)
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Figure 1.10.1 T1 recovery curve pre and post gadolinium administration. Before the
administration of gadolinium contrast agent, T1 is longer (dark; hypointense signal) (light
blue curve). After the administration of gadolinium contrast agent T1 is shortened (bright;
hyperintense signal) (dark blue curve).

1.10.2 T2 Shortening Agents
The most common T2 shortening agents are based on iron oxide. Iron-based contrast agents
cause protons or hydrogen atoms from water molecules in neighboring tissues to undergo
spin dephasing. The resulting spin dephasing from protons causes hypointense regions to be
visualized on MRI images. This causes protons to spin at different frequencies, eventually
resulting in rapid signal loss (hypointensity). The signal loss results in production of an
image artifact known as a ‘blooming artifact’. This is visualized in the MRI image as small
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black dots termed signal voids (80). The size of the blooming artifact is much larger than the
cell itself, which makes it easy to visualize (98).

Iron contrast agents were first used in liver imaging studies involving tumor detection
(93,107). Iron contrast agents are engulfed by liver Kupffer cells (specialized macrophages)
and these labeled liver cells cause a decrease in T2 (hypointense) of the normal liver tissue.
Liver cancerous lesions are visible as areas of increased signal intensiy (hyperintense) since
they are devoid of Kupffer cells (93,107).

Today, the field of ‘cellular MRI’ is largely based on the use of iron contrast agents to label
cells for tracking using MRI. There are many types of iron contrast agents such as ultra small
paramagnetic iron oxide (USPIO), super paramagnetic iron oxide (SPIO) and micron-sized
paramagnetic iron oxide (MPIO). They are usually categorized according to their
hydrodynamic diameter and size ranging from nanometers to micrometers (108-110). Nearly
all cell types can be labeled with sufficient amounts of iron to allow their detection by MRI.
Various studies have shown that the incorporation of iron into cells did not to interfere with
normal cellular functions such as proliferation and migration and did not impact viability
(80).

1.11 MRI of Human Brain Metastases
1.11.1 MRI Sequences used in Detection of Human Brain Metastases
MRI sequences typically used for detection of human brain metastases include pre- and postGd-DTPA T1wSE (111), T2wSE sequence and T2*w GRE. T1wSE with Gd-DTPA is used
for assessing BBB integrity (112), T2wSE is used for detection of the presence of edema.
The T2*w GRE pulse sequence is used for detection of susceptibility effects caused by
degradation products and melanin (111).
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1.11.2 MRI Appearance of Melanoma Brain Metastases
Melanoma brain metastases have variable MRI patterns, mostly attributed to the presence of
hemorrhage and melanin (113). MRI of hemorrhage itself has many different appearances.
Intracranial hemorrhages change over time as they go through acute to chronic phases where
the hemoglobin (Hb) molecule undergoes changes (114,115,116,117). The evolution of blood
degradation products at different stages of hemorrhage is shown in Table 1.11.2. This table
shows the stages of hemorrhage and associated MRI signal intensities (SI) (hyperintense,
isointense, hypointense) depending on the degradation product present. The MRI appearance
of blood degradation products due to hemorrhages also depends on the MRI field strength
and the MRI sequence employed (114).

Stages of
hemorrhage

Duration

Hyperacute

< 12h

hemorrhage

Blood
degradation
products of Hb
RBCoxyhemoglobin

Acute

Hours to

RBC-

hemorrhage

days

deoxyhemoglobin

Early subacute

Few days

RBC-

hemorrhage

methemoglobin

Late subacute

4-7 days to

Extracellular-

hemorrhage

1 month

methemoglobin

Chronic

Weeks to

Hemosiderin and

hemorrhage

years

Ferritin

T1w

T2w

SI

SI

↔ or ↓

↑

↔ or ↓

↓









↔ or ↓



Table 1.11.2. Stages of hemorrhage with accompanying changes in T1 and T2 signal
intensities (SI) of blood degradation products. RBC= Red Blood Cell, Hb= Hemoglobin
 = marked decrease in signal intensity, =marked increase in signal intensity, ↔ =
isointense signal intensity, ↓= decrease in signal intensity, ↑= increase in signal intensity.

27

Melanin has been shown to act as a T1 and T2 shortening agent (118). Amelanotic (the
absence of melanin pigmentation) melanomas tend to be hypointense or isointense relative to
surrounding brain tissue in T1wSE images and isointense to hyperintense in T2wSE images.
Melanotic melanomas tend to be hyperintense in T1wSE images and hypointense in T2wSE
images (46, 113). Some studies have shown that melanin impacts the T1 relaxation time
much more than T2 times. Gaviani et al. demonstrated a more profound T1 shortening effect
from melanin since they observed a direct correlation between melanin content and T1
hyperintensity. However they did not observe a correlation between melanin and
susceptibility effect (111). Similarly, Prekumar et al. observed no correlation between
melanin and T2 shortening in visceral melanoma metastasis (119).

1.12 MRI of Brain Metastases in Animal Models
MRI, has been used in various studies involving brain metastasis, whereby the
implementation of VEGF-A isoforms in a melanoma cell line Mel57 has been used in
Gadolinium contrast enhancement (CE) MRI for detection of brain lesions and to monitor
their permeability behaviour based on Gd-DTPA uptake. USPIO CE was also used to
characterize the vasculature of primary brain tumours (U87 and E34) and metastatic
melanoma brain lesions that were transfected with VEGF-A isoforms (67,120,121). MRI
techniques such as dynamic contrast enhancement (DCE-MRI) and diffusion weighted MRI
(DWI) have been used in animal studies of breast cancer brain metastasis (MDA-MB231BR) to acquire information about metastasis, permeability and cellularity in the brain and
bone microenvironment (122). Therapeutic treatments of brain metastases have also used
MRI to evaluate efficacy of the therapeutic drug agent. Antiangiogenic therapy ZA6474
(anti-VEGF) caused angiogenic growth of the melanoma transfected cell line Mel57-VEGFA to change to the vessel co-option phenotype (123). Gril et al. used MRI to monitor
treatment response of the HER2 beast cancer brain metastasis variant (MCF7-HER2-BR3)
toward Pazopanib. A 55% reduction in tumour volume was observed with administration of
Pazopanib compared to the vehicle control (no drug) (124). From prostate cancer, brain
metastasis studies using MRI JuanYin et al. showed that treatment response towards antiVEGF (AZD2171) administration resulted in two different functional responses of prostate
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cancer brain metastasis: tumour cells were able to extravasate into the brain tissue and a
heterogenous response in terms of therapy using anti-VEGF for individual brain lesions was
also evident (125). In a different study for prostate cancer brain metastasis using
AZD2171/Cedarinib, Yin et al. also demonstrated that DU145 prostate cancer brain and bone
metastasis growth was inhibited and mice bearing tumours showed a decrease in morbidity
and mortality (126).

Multimodality imaging has also been incorporated in animal studies using MRI and
bioluminescence imaging (BLI). Song et al. utilized the brain-seeking human breast cancer
cell line MDA-MB-231BR in MRI and BLI of rats, to monitor development of breast cancer
brain metastasis as well as disease progression in other anatomical sites/structures such as the
bone (127). MRI longitudinal studies involving animals has proven to be useful for
monitoring tumour development and progression. Perera et al. demonstrated the utility of
using MRI to monitor temporal and spatial development of experimental brain metastases in
the mouse brain for two metastatic breast cancer cell lines: MDA-MB-231BR and MDAMB-231BR HER2 (103). Cell tracking of tumour development after the extravasation was
demonstrated by Heyn et al. in which the fate of single- cells during the metastatic process of
breast cancer brain metastasis was monitored longitudinally (80). MRI longitudinal studies
involving permeability of breast cancer brain metastasis is a fairly new area of brain
metastasis research. Percy et al. had used a unique imaging protocol to investigate the
metastatic burden and alterations of BTB of breast cancer brain metastasis longitudinally in
mice (81). It was observed that small metastases were detected with bSSFP at the early time
points but they did not enhance with T1wSE using Gd-DTPA. In this model it was also
shown that altered BTB and total metastatic burden increased over time.

Although MRI has been used to investigate models of melanoma brain metastasis,
longitudinal studies have not been implemented for studying alterations of the BTB in a
clinically relevant model of melanoma brain metastasis.
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1.13 Thesis Overview and Objectives
The overall goal of this project was to use in vivo MRI to monitor the development of
melanoma brain metastases and the integrity of the BTB in a clinically relevant mouse
model.

The specific aims of this thesis were as follows:

1) To characterize a clinically relevant model of melanoma brain metastases.
2) To determine the percentage of melanoma brain metastases permeable to Gadolinium
contrast.

3) To understand when and why some brain metastases become enhanced while others
do not.

4) To examine histological differences between enhancing and nonenhancing
melanoma brain metastases.

Chapter 2 discusses the use of a clinically relevant animal model implemented in longitudinal
MRI studies monitoring changes in the BTB permeability of melanoma brain metastases over
time. Finally, Chapter 3 summarizes the key experimental findings and significance of this
study in relation to preclinical translational models as well as implications for clinical
disease. Lastly, study limitations and suggested future directions to further improve the
melanoma brain metastasis model are discussed.
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Chapter 2

2

In vivo assessment of melanoma brain metastases using
longitudinal MRI

Work presented in this chapter was done in collaboration with Dr. Ann Chambers, Dr. Paul
Lockman and Dr. Patricia Steeg. Catherine McFadden performed cell labeling with MPIO,
cell counting for cell injections and A2058 proliferation assay days 0 and 2, Perls Prussian
blue staining and cell culturing. Carmen Simedrea performed intracardiac cell injections.
Dextran perfusions, perfusions using 4% PFA, cutting of frozen as well as paraffin embedded
mouse brain tissue and H&E images of whole mouse brain was performed by Yuhua Chen
(Foster group laboratory manager). Dr. Emeline Ribot performed Molday USPIO tail vein
injections and Christiane Mallett imaged at day 14 pre and post Molday USPIO tail vein
injection. Custom-built MRI hardware, such as the gradient coil insert and the mouse
solenoid radiofrequency head coil, was designed and constructed by Dr. Brian Rutt’s
laboratory. The remaining procedures including MR scanning, mouse anesthesia,
intraperitoneal (IP) injections of gadolinium contrast, monitoring health status and weekly
weighing of mice, data analysis, tissue dissection into different brain regions (frontal,
midbrain, and hindbrain) in preparation for embedding, tissue embedding of mice brains in
O.C.T medium and paraffin wax, H&E staining of frozen and paraffin mouse brain tissue
sections, microscopic analysis of H&E slides and fluorescence microscopy, cell counts for
A2058 cell culture proliferation assay days 5 and 7 and imaging mouse brain at day 31 pre
and post Molday USPIO tail vein injection were performed by Mariama Henry.
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2.1 Introduction
Malignant melanoma is the most dangerous form of skin cancer (1). The incidence of
malignant melanoma continues to rise, especially among young adults (1). A common
complication for patients with malignant melanoma is metastasis to the brain (2). Patients
with metastatic melanoma have a 40% to 60% risk of developing brain metastases (3).
Moreover, autopsy results have shown that metastases in 70-90% of brains from patients that
died with stage IV melanoma (3,4), metastasize to the brain compared to other primary
tumours, such as lung and breast cancer (3,5). The prognosis for patients with melanoma
brain metastasis remains dismal with a median survival of 1-2 months without treatment (68), 4-6 months with treatment (6,9) and a 1-year survival rate in less than 13% of patients
(10). Chemotherapeutics are not able to cross the blood-brain barrier (BBB) and
consequently have limited efficacy in the treatment of brain metastases (5,11).

The local BBB associated with brain tumours is referred to as the blood-tumour barrier
(BTB) (12-15). Several studies have now described significant heterogeneity in the
permeability of the BTB associated with individual brain metastases (16,17). Lockman et al.
showed that the BTB of breast cancer brain metastases in mice exhibited significant
heterogeneity in permeability to dextran and that permeability was unrelated to the size or
morphology of metastases (16). Zhang et al. examined brain metastases produced by 8
human cancer cell lines and reported that permeability to sodium fluorescein varied
depending on tumour type and was related to tumour morphology and size. Small compact
metastases were not permeable until they reached 0.2mm2 and diffuse metastases were
permeable only when they coalesced to form a large mass (18). These were both ex vivo
experiments conducted at specific endpoints and therefore provide only a snapshot of the
permeability status of a metastasis.

Magnetic resonance imaging (MRI) has also been used to evaluate BBB integrity in vivo
(18-28). Gadolinium contrast agents such as Gadopentatic acid (Gd-DTPA) are used
routinely in MRI to demonstrate BBB breakdown (17,29-33). Gadolinium cannot cross an
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intact BBB, therefore extravascular enhancement in MR images after administration of GdDTPA indicates a leaky BBB, or increased permeability (34). Percy et al. used Gd-DTPA
enhanced MRI to evaluate BBB permeability and tumour burden in a mouse model of breast
cancer metastasis to the brain (17). This paper showed significant heterogeneity in the
permeability of these brain metastases with increasing numbers of permeable tumours over
time. This study also revealed that small metastases could be detected using the balanced
steady state free precession (bSSFP) imaging sequence but they were not visible with GdDTPA.

Brain metastases due to melanoma have not been studied longitudinally in vivo. Leenders et
al. used Gd-DTPA enhanced MRI to demonstrate that vascular endothelial growth factor-A
(VEGF-A) expressing melanoma brain metastases were visible after Gd-DTPA injection due
to leaky peritumoral vasculature but brain metastases that did not express VEGF-A went
undetected (19). This study looked at the brain metastases at a single time point. Longitudinal
imaging allows the integrity of the BBB to be monitored over time to observe how it changes
with tumour development and in response to therapy.

In the following study we used longitudinal MRI to characterize a clinically relevant model
of melanoma brain metastases and we applied the imaging approach developed by Percy et
al. (17) to assess BTB integrity and total metastatic burden at four different time points
during metastasis development. Our goal was to determine what percentage of melanoma
brain metastases were permeable to Gd-DTPA, and therefore considered to have a leaky
BTB, and to learn more about when and why certain brain metastases are more permeable
than others.
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2.2 Materials and Methods
2.2.1 Experimental groups
Two experiments were performed which used the methods described below. The goal of
experiment 1 was to characterize the MRI appearance, number and size of brain metastases
that developed approximately one month following the intracardiac injection of 50,000
A2058 human melanoma cells into nude mice. Nine mice were imaged once, at the endpoint
of the experiment. Experiment 2 was designed to monitor the development of these brain
metastases over time in two groups of mice. This included MRI methods that measured the
total brain metastatic burden and evaluated the BTB integrity at multiple time points. Two
groups of 4 mice were scanned at multiple time points post cell injection.

2.2.2 Cell culture and cell viability assays
The A2058 human metastatic melanoma cell line was obtained from American Type Culture
Collection (ATCC)® (cell line provider Cedarlane Labs, Canada). Cells were cultured at
37°C, 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) + 10% Fetal Bovine Serum
(FBS) (Gibco® Invitrogen). Cells were passaged every 2-3 days.

A2058 cells were incubated overnight with micron sized paramagnetic iron oxide (MPIO)
nanoparticles that were conjugated to either Flash Red (660nm excitation and 690nm
emission spectra) or Dragon Green (480nm excitation and 520nm emission spectra) (Bangs
Laboratories, USA). The green fluorescent MPIO was used for experiments where we also
perfused mice with a red fluorescent dextran probe (see below). A trypan blue exclusion
assay was performed prior to and after intracardiac cell injections for both MPIO-labeled and
unlabeled cells to measure cell viability. Cytospins were performed for unlabeled and MPIOlabeled cells and Perls Prussian Blue (PPB) staining for iron was performed to assess MPIO
uptake.
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A cell proliferation assay was performed to determine the impact of MPIO labeling on
cellular function. The A2058 melanoma cells were plated at a density of 2x105 cells/ml in
both T75 (cell culture flask with 75cm2 growth surface area) and T25 (cell culture flask with
25cm2 growth surface area) flasks. Two different flasks were used to see which housed the
best environment for the experiment and the optimum growth of cells. Four cell culture
flasks containing unlabeled and labeled (two T75 and two T25) A2058 human melanoma
cells were counted manually using a hemocytometer. Unlabeled and labeled A2058 cells
were counted on days 0, 2, 5 and 7 to generate a growth curve showing cell proliferation.
Growth rates were determined from the linear regression for the exponential growth curve
equation generated in Microsoft Excel software. The formula for the exponential growth
curve was as follows: y =aebt where y = cell number after time t, a = the initial cell number,
b = the growth constant (in this case units are day-1), t = time (in this case days).

2.2.3 Animal Model
Athymic immunodeficient female nude mice (strain #088 Foxn1 Nu/Nu) age 6-8 weeks old
were used (Charles River laboratories, Saint Constant, Quebec) in accordance with an
approved animal use protocol (Appendix A: Animal Use Protocol). Mice were housed in a
barrier facility at the Animal Care and Veterinary Services (ACVS) at Western University.
For cell injections, mice were anesthetized with a mixture of 100% oxygen (flow rate 2 litres
per minute) and isofluorane (3% for induction, 1-1.5% for maintenance). A U-100 insulin
syringe with a 28G ½ needle (Becton Dickinson) was used to inject 50,000 MPIO-labeled
A2058 cells in 100µl Hank’s Balanced Salt Solution (HBSS) into the left ventricle of the
beating mouse heart. Mice were weighed and monitored weekly for signs of health or
sickness (disease onset was prevalent at week 3 and more pronounced at week 4 when mice
became moribund and cachexic due to the aggressiveness of malignant melanoma).

2.2.4 Imaging
All mice were imaged using a 3 Tesla (T) General Electric (GE) MR750 MRI clinical
scanner equipped with a custom-built gradient coil insert (maximum gradient coil
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strength = 500 mT/m and maximum slew rate = 3,000 T/m/sec) and a 1.5-cm diameter
solenoidal radiofrequency (RF) coil for the mouse head. Before scanning, mice were
anesthetized with 3% isofluorane for induction and lowered to 1-2% for maintenance. During
scanning, all mice were kept warm through exploitation of heat convection (heated saline
bags were attached to the insert tray of the gradient coil).

To evaluate the success of the intracardiac cell injection, mice were imaged using the
balanced steady-state free precession (bSSFP) imaging sequence. The following parameters
were used: Field of View (FOV) = 2.0 cm, repetition time (TR) = 16 ms, echo time (TE) = 8
ms, flip angle (FA) = 35°, image matrix = 100 x 100, number of excitations (NEX) = 1,
receiver bandwidth (rBW) = ±41.67 kHz, phase cycles (PC) = 4. The scan time was 13:41
min and the spatial resolution was 200 x 200 x 200 µm.

For experiment 1, higher resolution bSSFP images were acquired on day 25 (n=5) or day 26
(n=4) post cell injection. The following imaging parameters were used: FOV = 1.5 cm,
TR/TE=8/4 ms, FA = 35°, image matrix = 150 x 150, slice thickness = 200 µm, NEX = 2,
rBW = ±41.67 kHz, PC = 8. The scan time was 30:45 min and the spatial resolution was 100
x 100 x 200 µm. These images were used to count the number of metastases and to measure
the volume of each metastasis.

For experiment 2, two imaging sequences were used on consecutive days at four different
time points: days 21/22 post cell injection, days 24/25 post cell injection, days 27/28 post cell
injection, and days 30/31 post cell injection. On the first day of each time point T1 weighted
spin echo (T1wSE) images were acquired after the intraperitoneal (IP) injection of
Gadopentatic acid (Gd-DTPA; 200µl undiluted, Magnevist™, Schering, USA) to assess the
integrity of the BBB. Images were acquired 60 minutes post Gd-DTPA injection. The
following parameters were used: frequency FOV = 2 cm, phase FOV = 1 cm, TR = 600 ms,
TE = 20 ms, image matrix = 128 x 128, NEX = 12, rBW = ±15.63 kHz. The scan time was
15:45 min and the spatial resolution was 156 x 156 x 500 µm. On the second day, bSSFP
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images were acquired for the same mice to assess total metastatic tumour burden. The
imaging parameters were the same as for bSSFP images acquired in experiment 1. During
scanning of the first group of 4 mice, some mice had to be sacrificed and these were replaced
with others, so that 4 mice were imaged at each time point although these were not always
the same 4 mice. For the second group of mice all four animals were imaged 8 times each, at
all of the pre-determined time points.

2.2.5 Image analysis
OsiriX™ image software (open source) was used for image visualization and analysis. The
bSSFP images were used to count the number of metastases and to measure the volumes of
individual metastases within the whole brain; this represented the total number of metastases
(see Appendix C for total metastatic burdens of mice). The volumes of metastases were only
measured for the first group of mice in experiment 2. In total the volumes of 120 individual
metastases were calculated. To measure the volume, a manual trace method was used in
which tumour borders were manually outlined in each image slice and a final algorithmic
computation was performed to obtain a three-dimensional (3D) tumour volumetric
measurement (mm3). The T1wSE images were used to determine which metastases enhanced
after Gd-DTPA. T1wSE images were viewed along with bSSFP images at all four time
points. Enhancing metastases were defined as those with an increase in signal intensity
hyperintensity compared to the surrounding mouse brain tissue, in regions where bSSFP
images revealed a metastasis. Metastases classified as nonenhancing were not visible in
T1wSE images but were present in bSSFP images.

Due to differences in coverage of the mouse brain for both sequences not all enhancing
metastases were evaluated for the T1wSE scan portion. Enhancing metastases were evaluated
from frontal to hindbrain, which began at slice 1 and ended at slice 11 for T1wSE images.
bSSFP images that had a total of 184 image slices were compared simultaneously with
T1wSE post Gd-DTPA images. The image slices for bSSFP were matched according to the
start and end image slices for the T1wSE post Gd-DTPA images. Some metastases were
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visible in bSSFP images but were not evaluated as enhancing or nonenhancing because there
was no corresponding T1wSE post Gd-DTPA image.

Parenchymal metastases were defined as those located within the brain tissue. Metastases
were classified as meningeal if at least one side of the metastasis appeared to be located
along the surface of the brain. To help verify that metastases were meningeal OsiriX™ image
software was used. In OsiriX™, the orthogonal reslice tool was utilized for reslicing the
acquired axial MRI images in the X (sagittal) and Y (coronal) planes. Scrolling through the
image slices in X and Y planes were performed to confirm the status of the metastasis as a
meningeal metastasis. Meningeal metastases were further classified as originating from either
the pia (leptomeninges) or dura mater according to the MRI appearance. The observation of
cerebrospinal fluid (CSF) between the brain tissue and the tumour suggested that the
metastasis had originated from the dura mater.

2.2.6 Histology and Microscopy
Mice were sacrificed after scanning and brains were prepared for microscopy. Brains were
either embedded in paraffin or Optimal Cutting Temperature (O.C.T) medium. For paraffin
embedding, mice were perfused with 4% paraformaldehyde (PFA) and then brains were
removed and cut into sections with image guidance then placed in tissue embedding
cassettes. The cassettes were placed in 70% ethanol before paraffin embedding. Using a
microtome, brains were sectioned into 10-µm tissue sections and two sections per slide were
placed on positive glass slides. Slides were stained with Hematoxylin and Eosin (H&E) using
an automated stainer (Leica Microsystems).

For frozen tissue sections, mouse brains were removed after perfusion and placed in
increasing concentrations of sucrose 10%, 20%, 30% (overnight) to cryoprotect tissues
before embedding. Mouse brains were embedded (positioned dorsal to ventral) in O.C.T
medium with the ventral side facing the bottom surface of the cryomold. Using a cryostat
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(Leica Microsystems) frozen sections were cut at a thickness of 20-µm with four sections
placed on positive glass slides. Slides were placed in a -20°C freezer for long-term storage.

For some mice an ex vivo permeability assay was performed. Four mice were anaesthesized
with 3% isofluorane and perfused via tail vein injection with 200µl of 1.5 mg Dextran Texas
Red (this molecular dye can only cross a non-intact BBB). The Dextran Texas Red was
allowed to circulate for 20min prior to mouse sacrifice. After sacrificing, mice were perfused
with 4% PFA and brains were removed and frozen tissue sections were prepared as described
above. Prior to tissue sectioning, mouse brains were temporarily stored at -80°C. After
sectioning, the remaining frozen tissue was stored at -20°C.

Images of H&E stained and fluorescence frozen sections were acquired with a Zeiss Axio
Imager A1 microscope (Zeiss, Germany) using a Retiga Exi (QImaging, Canada) digital
camera. Image Pro Plus software Version 7 was used for histological image editing. For
fluorescence image analysis, slides with frozen mouse brain sections were analyzed first for
dextran leakage. After acquiring Dextran Texas Red (595nm excitation and 615nm emission
spectra) fluorescence images, frozen tissue sections were H&E stained using an automated
slide stainer (Leica Microsystems). Both H&E images (paraffin and frozen sections) as well
as fluorescence images were matched as close as possible with MRI images. An exact match
is difficult to achieve due to differences in slice thicknesses for MRI and histology.

2.2.7 Statistical Analyses
Statistics were performed using GraphPad Prism® software Version 5.0. The numbers of
metastases in the characterized model were represented as mean ± Standard Deviation (SD).
Comparison of meningeal vs. parenchymal brain metastases was performed using unpaired
student t-tests; data was represented as mean ± Standard Deviation (SD). Comparison of
groups (enhancing vs. nonenhancing brain metastases) at each time point during the
longitudinal studies was performed using the Kruskal-Wallis test followed by the posthoc
test: Dunn’s Multiple Comparison Test. The level of statistical significance was p<0.05.

49

2.3 Results
2.3.1 Cell Labeling
To visualize cells with MRI they were labeled with iron oxide contrast agent. Figure 2.3.1
shows images of PPB stained cells for unlabeled (A) and MPIO-labeled (iron-labeled) (B)
A2058 cultured cells. After PPB staining, nearly all labeled A2058 cells stained positively
for iron, as shown by blue punctate iron deposits. Without MPIO labeling, A2058 cells did
not stain blue after PPB. The cell viability prior to injection was 93.8% for unlabeled A2058
cells and 95.8% for MPIO-labeled A2058 cells. Cell viability after cell injection was 97.8%
for unlabeled A2058 cells and 89.5% for MPIO-labeled cells. To examine the effects of iron
labeling on the proliferative potential of A2058 cultured cells, a proliferation assay was
performed. Cell numbers for unlabeled and MPIO-labeled A2058 melanoma cultured cells
were generated based on manual cell counts at days 0, 2, 5 and 7.

Fig 2.3.1 Perls Prussian blue staining of iron-labeled and unlabeled human melanoma
A2058 cultured cells. (A) Unlabeled (no iron present) and (B) MPIO-labeled (which are
iron-labeled) A2058 human melanoma cells. Scale bars = 100µm

Figure 2.3.2 shows the growth curves for unlabeled and MPIO-labeled melanoma cells.
Overlap of the exponential curves is observed indicating that growth rates were similar for
unlabeled and labeled cells (grown in T75 flasks and T25 flasks) at all four time points. The
grow rate constants were as follows 0.3581 day-1 (unlabeled cells T25 flask), 0.4008 day-1
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(labeled cells T25 flask), 0.3901 day-1 (unlabeled cells T75 flask) and 0.4043 day-1 (labeled
cells T75 flask). Thus growth rates were similar for unlabeled and MPIO-labeled melanoma
cells irrespective of the cell culture flask, growth area and iron labeling. The cell viability
was also measured at each time point, by trypan blue exclusion, and varied from 88 to 100%.

Fig 2.3.2. Cell proliferation assay. Growth curves for unlabeled and Bangs (MPIO) labeled
A2058 melanoma cells. All four plots show similar growth rates indicating that iron labeling
did not affect this biological function of these cells.

2.3.2 Imaging
To confirm that the intracardiac cell injections were successful, short bSSFP scans (short
scan time) were acquired and the brain images evaluated for the presence of signal voids,
which represent iron-labeled cells. Figure 2.3.3 shows a representative bSSFP image slice
obtained on day 1 post cell injection where numerous discrete regions of signal void (white
arrows) throughout the brain indicate a successful injection. The success rate for this
experiment (referring to experiment 1) was 90% (9/10 mice).
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Fig 2.3.3 bSSFP image of a mouse brain day 1 post cell injection. The black dots
represent areas of signal loss (white arrows).

Figure 2.3.4 shows the appearance of melanoma metastases in the mouse brain in bSSFP
images. Compared to the surrounding brain tissue, melanoma brain metastases in this mouse
brain appeared with increased signal intensity (hyperintense). Both parenchymal and
meningeal metastases were detected throughout the brain. Parenchymal metastases were
characterized as those located within, and surrounded by, the brain tissue and having no
contact with the surfaces of the brain at first detection. Examples of parenchymal metastases
for the mouse brain shown in figure 2.3.4 can be seen in A, D&G (white arrows). Meningeal
metastases were defined as those with at least one side adjacent to the surface of the brain
when first detected. There were two different types of meningeal metastases observed. The
first type of meningeal metastasis appears to originate from the outer meninges, the dura
mater (refer to figure 2.3.5). In MRI images these metastases are located between the skull
and CSF. The second type of meningeal metastasis appears to originate from the inner
meningeal layers (leptomeninges). Examples of meningeal metastases for the mouse brain
shown in figure 2.3.4 can be seen in C, E&F (yellow arrows). Figure 2.3.4 also shows
examples of parenchymal metastases for the mouse brain that can be seen in A, B,D & G-I
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(white arrows). Enlarged ventricles (figure 2.3.4 D, E, and F) were also observed. There was
a wide range of volumes for both parenchymal and meningeal metastases in this mouse brain.
The mean volume of all metastases was 0.532 mm3. The volumes did not appear to depend
on brain location. The largest metastasis measured was 2.47mm3 and the smallest metastasis
measured was 0.0438 mm3; both were located in the hindbrain.

Figure 2.3.4 bSSFP images showing the appearance and spatial distribution of
melanoma metastases in a representative mouse brain. Representative bSSFP axial image
slices of brain metastases (both meningeal; yellow arrows and parenchymal; white arrows)
from the same mouse. All metastases (A-I) appeared hyperintense compared to the
surrounding brain tissue. In (D, E &F), the brain ventricles appeared hyperintense and were
enlarged.

Another example of a meningeal metastasis (yellow arrow) that appeared to originate from
the dura mater is shown in figure 2.3.5 below. This metastasis appeared to be compressing
and displacing the normal brain tissue.
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Figure 2.3.5 bSSFP image of a melanoma meningeal metastasis in a mouse brain. bSSFP
image of a melanoma metastasis (yellow arrow) that appeared to be growing from the dura
mater (most outer layer) of the brain meninges.

MRI detectable metastases were counted for 9 mice, n=5 mice from images acquired at day
25 and n=4 mice from images acquired at day 26. Overall, the number of metastases that
developed at these endpoints ranged from 5 to 19 per mouse brain. The average number of
metastases per mouse brain was 11 (refer to figure 2.3.6).
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Fig 2.3.6 Numbers of melanoma brain metastasis after 50,000 cells injected. A cell
injection of 50,000 A2058 melanoma cells produced between 5 and 19 brain metastases. 5/9
mice developed more than 10 brain metastases and 4/9 mice developed fewer than 10
metastases at days 25 and 26. Data represented as mean ± SD

The mean number of meningeal and parenchymal brain metastases that developed is shown
in figure 2.3.7. Significantly more parenchymal metastases were observed than meningeal
metastases (approximately 80% were parenchymal). See Appendix D for total, mean
metastasis numbers and volumes for meningeal and parenchymal brain metastases.
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Fig 2.3.7 Mean number of meningeal and parenchymal melanoma brain metastases.
Using an unpaired t-test, a statistically significant difference (p=0.013) was evident amongst
the mean parenchymal (9.00 ±1.74) and mean meningeal (2.44±0.626) metastases. Data are
mean ± SD

H&E staining of the brain sections showed that meningeal and parenchymal metastases had
similar morphologies; they were hypercellular and had little associated edema. In Figure
2.3.8 the MRI is shown (A) alongside a low power H&E staining of the corresponding whole
brain section (B). A meningeal metastasis (box in B) is shown at 5x magnification in (C).
This metastasis appeared as a tight cluster of cells with little associated edema. At 100x
magnification (box in C) groups of melanoma cells are seen (D).
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Figure 2.3.8 MRI and H&E histology for A2058 melanoma meningeal brain metastasis.
(A) bSSFP MRI showing a meningeal metastasis (white arrow) and (B) whole brain H&E
that correlates to MRI, scale bar = 1mm. Meningeal metastasis (C) at 5x magnification, scale
bar = 1mm. (D), 100x magnification (inset C) showing groups of melanoma cells, scale bar =
50µm.

Figure 2.3.9 shows an MRI image of a parenchymal metastasis (A) and the corresponding
whole brain section H&E staining is shown in (B). The H&E section at 5x (C) shows a
hypercellular mass of cells that was located next to the left lateral ventricle (white arrow). At
100x magnification (D), the black arrow points to what appeared to be a small area of edema
in between the melanoma cells.
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Figure 2.3.9 MRI and H&E histology for A2058 melanoma parenchymal brain
metastases. The bSSFP MRI (A) image shows parenchymal brain metastases as hyperintense
areas (white arrows). (B) Shows the corresponding whole brain H&E section scale bar =
1mm. (C) One of the metastases (box in B) is shown at higher magnification scale bar =
1mm. The white arrow in (C) points to the choroid plexus located in the left lateral ventricle.
(D) The black arrow points to what appears to be edema surrounded by melanoma cells (box
in C), scale bar = 50µm.

2.3.3 Longitudinal MRI
The model of melanoma brain metastasis characterized above was implemented in a
longitudinal MRI experiment to monitor the development of brain metastases and to evaluate
the integrity of the BTB over time. Mice were imaged in two groups so that the amount of
time to image all mice on each day was more reasonable (the time required to scan 5 mice
with bSSFP was approximately 5 hours and the time required to scan 5 mice with T1wSE
was approximately 4 hours). The total tumour burden was determined by counting all
metastases in bSSFP images (see Appendix C for total metastatic burden of mice at each time
point) at the endpoint of the longitudinal experiment (day 31) (which was later than for the
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characterization experiment; days 25/26), we observed a range of 4 to 20 brain metastases
per mouse. Mice with more than 20 brain metastases (n=3) did not survive until this
endpoint. Approximately 85% of the metastases were determined to be parenchymal.

Figure 2.3.10 shows T1wSE post Gd-DTPA and bSSFP images for a representative mouse.
(A&B) are T1wSE post Gd-DTPA images and C&D are bSSFP images. The images shown
in (A&C) were obtained on days 24 and 25 and the images shown in (B&D) were acquired
on days 27 and 28. A single metastasis was visible in the bSSFP image on day 25 but did not
appear in the T1wSE post Gd-DTPA image acquired the day before. At the next imaging
session (B&D), the same metastasis appeared in both the bSSFP image and T1wSE post GdDTPA image. This example showed that there are metastases that do not enhance after GdDTPA, and therefore are not associated with a disrupted BTB, but are detectable in bSSFP
images. It also showed that the integrity of the BTB associated with melanoma brain
metastases can change over time.
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Figure 2.3.10 bSSFP and T1wSE post Gd-DTPA images of brain metastases.
T1wSE+Gd-DTPA and bSSFP at early (days 24/25) and later time points (days27/28) shows
the sensitivity of bSSFP to brain metastases (nonenhancing) that were undetectable using
T1wSE+Gd-DTPA at the early time point. In (C) a single brain metastasis at day 25 was
visible in the bSSFP image but not in theT1wSE post Gd-DTPA acquired the day before. At
day 27 (B) this metastasis was enhancing and in the bSSFP image (D) appeared to have
increased in size. Some metastases were detected in bSSFP but not in T1wSE post Gd-DTPA
images.

Another interesting observation was that within mice there was substantial heterogeneity in
the number of enhancing metastases. Figure 2.3.11 illustrates this finding. A-D are T1wSE
post Gd-DTPA images and E-H are bSSFP images. In (A) at day 21, only one enhancing
metastasis was visible. This same metastasis was also visible in bSSFP images acquired on
day 22 (E). At the following imaging session on day 24 (B) the same enhancing metastasis
was still visible in the post Gd-DTPA image and had increased in size, however, two
metastases were now visible at day 25 in the bSSFP image (F). At the next imaging session
C&G, the same metastases were observed. The larger metastasis at the base of the brain was
a meningeal metastasis and the smaller metastasis towards the top of the brain was
parenchymal. At the final imaging sessions day 30 (D) and day 31 (H), two enhancing
metastases were detected in the T1wSE post Gd-DTPA image and three metastases were
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visible in the bSSFP image (H). This example showed that multiple metastases could be
found within the same mouse brain with varying Gd-DTPA enhancement profiles.

Figure 2.3.11 Heterogeneity in enhancement for A2058 melanoma brain metastases.
MRI images A-D are T1wSE+Gd-DTPA images and E-H are the corresponding bSSFP. One
metastasis was seen as enhancing from days 21 to 27 (A-C). At day 30, a second metastasis
was visible as enhancing (near the top of the brain). In the bSSFP images (E-H) the number
of metastases increased over time. At day 31 (H) three metastases were detected but only two
metastases were visible as enhancing at day 30 (G).

In Table 2.3.1 the number of metastases that enhanced at each time point are presented for
each of the mice. This is reported as X of Y where X is the number of enhancing metastases
in T1wSE post Gd-DTPA images and Y is the number of metastases identified by bSSFP.
Note that the number of metastases identified by bSSFP, reported in this table, is not the total
metastatic burden (see Appendix C for total metastatic burden in mice at each time point). At
the first imaging time point only 2 of 9 mice (mice 6 and 7) had metastases that enhanced in
T1wSE post Gd-DTPA images; each mouse had just one enhancing brain metastasis. At the
second imaging session enhancing metastases were detected in 7 of the 9 mice. At the last
imaging session all of the surviving mice had more than one enhancing metastasis. One
mouse had no enhancing metastases throughout the entire experiment (mouse 3). This mouse
was sacrificed early due to signs of poor health.
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With the exception of one animal (mouse 5) the percentage of metastases that enhanced
increased with time. Mouse 5 was a unique case, the number of enhancing metastases
changed from 6 out of 14 to 3 out of 14, between the third and fourth imaging sessions,
because a prominent area of signal void developed within 3 of the metastases, most likely
due to hemorrhage, obscuring the visualization of the metastases. Enhancing metastases
never changed to nonenhancing metastases in our study. Two mice died during the scanning
sessions on day 25; both had relatively high metastatic burden. The images also showed that
they had enlarged ventricles (hydrocephalus). Both of these mice had very large meningeal
metastases at the base of the brain. Furthermore, the volume of the metastases measured in
these mice at day 25 was significantly larger than those of the other mice at this time point.
Mouse 2 and mouse 4 had the fewest metastases at endpoint and also the highest percentage
of enhancing metastases.

Table 2.3.1 Number of enhancing melanoma brain metastases over time.

bSSFP images also showed regions of low signal that developed within metastases over time.
Figure 2.3.12 shows bSSFP images obtained on days 22, 25, 28 and 31 post cell injection.
Two metastases were present; a parenchymal metastasis was visible at day 22 as a region of
signal hyperintensity (yellow arrow) and a different parenchymal metastasis (blue arrow)
remained isointense throughout the study (day 22 to day 31), this metastasis was not visible
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in bSSFP images but was identified in histological analysis (refer to figure 2.3.12, E). At day
25, the metastasis (yellow arrow) appeared to increase in size and a small dark void appeared
within it. At day 28 the metastasis (yellow arrow) and the region of signal hypointensity were
both larger. By day 31 the metastasis (yellow arrow) itself was no longer visible in this image
slice. Instead, what is referred to as a blooming artifact, appeared in its place, the result of a
large accumulation of superparamagnetic species which the H&E staining for this metastasis
indicated was due to hemorrhage. The bottom panel shows the corresponding whole brain
H&E staining (E) to the bSSFP image in (D). (F) Shows the 40x magnification of the
hemorrhagic metastasis from the box in E. The 100x magnification in (G) is a region in (F)
that shows the presence of blood encircling and nested within the melanoma cells (white
arrows).

An important observation was made during the comparison of MRI and histology. In several
mice, metastases that were detected in H&E histology were not obvious in either bSSFP or
T1wSE images. When the images were evaluated retrospectively we found that some of these
metastases appeared with the same signal intensity as the surrounding brain tissue in bSSFP
images (isointense). An example of an isointense brain metastasis can be seen in Figure
2.3.12 (blue arrows).
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Figure 2.3.12 bSSFP images show development of a hemorrhagic metastasis and
nonhemorrhagic metastases. Top panel: bSSFP images from the same mouse. (A-D)
shows development of a parenchymal brain metastasis (yellow arrows) in the frontal brain
region at four time points. The metastasis increased in size over time and started to show
signs of signal loss (dark circle in center) at day 25. At day 31 the metastasis was no longer
visible due to the blooming artifact. The numbers in white (lower right of each panel)
represent the total metastatic burden at each time point indicated. The blue arrows point to a
metastasis that appears isointense in bSSFP images. Bottom panel: (E) whole brain H&E
corresponding to (D top panel), blue arrow points to the metastasis that is visible in the H&E
image but is isointense (blue arrows) in bSSFP images (A-D). Two nonhemorrhagic
metastases are also visible near the top left hemisphere of the brain, scale bar = 500µm, (F)
10x magnification of hemorrhage from box in A scale bar = 500µm. (G) Hemorrhage was
observed (white arrows) in the metastasis from (F), scale bar = 100µm.
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The volumes of metastases from experiment 2, group 1 (see table 2.3.1), were measured at
each time point from bSSFP images (for reliability of volume measurements refer to
Appendix B for inter- and intra-observation (35,36) volume measurements of melanoma
brain metastases). This is presented in Figure 2.3.13. There was a large range of volumes for
metastases at each time point. The volumes increased over time for both enhancing and
nonenhancing metastases. In these 4 mice (from experiment 2, group1) there were no
enhancing metastases detected at day 21. The smallest MRI detectable metastasis was
0.0143mm3 and was detected at day 25. The largest metastasis was 42.9mm3 and was
detected at day 31. There was no statistically significant difference in the volumes of
enhancing and nonenhancing metastases at any time point.

Figure 2.3.13 Volumes of enhancing and nonenhancing of A2058 melanoma brain
metastases at each time point. Although a trend for increasing volume was seen over time,
there was no statistical difference (p<0.05) in volumes of enhancing and nonenhancing
metastases. Bars represent medians.
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Figure 2.3.14 shows bSSFP images for both small and large enhancing and nonenhancing
metastases.

Figure 2.3.14 Representative bSSFP images comparing volumes for nonenhancing and
enhancing melanoma brain metastases from the same mouse. A&B show enhancing
metastases (with their accompanying volumes) in the midbrain-hindbrain (A), and frontal
regions (B). C&D show nonenhancing metastases in olfactory-frontal (C), and frontal regions
(D).

Figure 2.3.15 illustrates some of the different patterns of enhancement over time for
individual metastases. For example, some metastases were enhancing when they were first
detected and remained enhancing throughout the study (light blue line), some metastases
never enhanced (pink line), many metastases first appeared as nonenhancing but changed to
enhancing at later time points (light red, dark blue and dark purple lines). We also observed
new metastases that appeared at the last imaging time point (red, green and light purple dots);
these late appearing metastases were all nonenhancing. This figure also shows that the
volume of a metastasis did not predict whether or not it would be an enhancing metastasis.
For instance at the late time point (day 31) large enhancing and nonenhancing metastases
were observed as well as small enhancing and nonenhancing metastases. Metastases that
were first detected at the last imaging session were always nonenhancing.
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Figure 2.3.15 Differences in patterns of enhancement over time for A2058 melanoma
brain metastases. Each line represents a different metastasis. Individual metastases showed
varying enhancement patterns as shown by the colored lines; light blue line= metastasis first
detected as enhancing and remained enhancing, pink line= metastasis that never enhanced,
light red, dark blue and dark purple line= metastases first appeared as nonenhancing but
changed to enhancing at later time points. Red, green and light purple dots= late appearing
metastases were nonenhancing. Hollow circles represent enhancing metastases and solid
circles represent nonenhancing metastases.

We compared our in vivo permeability data obtained with T1wSE post Gd-DTPA images
with the ex vivo permeability using Dextran Texas Red; this dye can only leak through a nonintact BBB. Figure 2.3.16 shows T1wSE post Gd-DTPA (A) and bSSFP (B) images of an
enhancing metastasis (white arrows) and the corresponding dextran fluorescence and H&E
images (C&D) for this single metastasis. The fluorescence image (C) shows the presence of
red fluorescence associated with the tumour, which suggests that this metastasis was
permeable to the dextran. The corresponding H&E shows that the enhancing metastasis was
hypercellular.

67

Figure 2.3.16 Representative T1wSE post Gd-DPTA and bSSFP images of an enhancing
metastasis with corresponding dextran fluorescence image and H&E histology. (A)
T1wSE post Gd-DTPA image. (B) bSFFP image. (C) 10x magnification dextran fluorescence
image of an enhancing metastasis (A, white arrow) showing dextran leakage within the
metastasis, scale bar = 971µm. (D) H&E image showing 10x magnification of the enhancing
metastasis (white arrow, A), scale bar = 971µm.

Figure 2.3.17 shows T1wSE post Gd-DTPA (A) and bSSFP (B) images of a nonenhancing
metastasis (white arrow). There appeared to be minute dextran fluorescence (C) in the
tumour interstitial space suggesting that BTB regions within this metastasis were not
completely intact.
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Figure 2.3.17 Representative T1wSE post Gd-DPTA and bSSFP images of a
nonenhancing metastasis with corresponding Dextran and H&E histology. (A) T1wSE
post Gd-DTPA image. (B) bSFFP image. (C) 10x magnification dextran fluorescence image
of a nonenhancing metastasis from (B, white arrow)) showing little to no dextran leakage
within the metastasis, scale bar = 971µm. (D) H&E image showing 10x magnification of
metastasis in (B), scale bar = 971µm.

Figures 2.3.18 shows enhancing and nonenhancing metastases that were situated in different
brain locations. Figure 2.3.18 shows T1wSE post Gd-DTPA images (A&D) and bSSFP
images (B&E) at day 31. The insets (B&E) show enhancing and nonenhancing metastases
respectively located in different brain locations; frontal-midbrain (B) and midbrain brain
region (E). (C&F) are the corresponding H&E 10x magnifications from the boxes in (B&E).
Hypercellularity was observed for both enhancing and nonenhancing metastases.
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Figure 2.3.18 Representative T1wSE post Gd-DPTA and bSSFP images of an enhancing
and nonenhancing metastasis with corresponding H&E histology. A&D T1wSE post GdDTPA images and B&E bSSFP images. (A) Enhancing metastasis (blue arrow), (B)
corresponding bSSFP metastasis to (A, blue arrow), (D) no visible enhancing metastasis in
T1wSE with Gd-DTPA, (E) nonenhancing metastasis visible with bSSFP. (C) H&E image of
an enhancing metastasis in the frontal-midbrain region showing hypercellularity, scale bar =
971µm. (F) H&E image of a nonenhancing metastasis in the midbrain region, showing
hypercellularity, scale bar = 971µm.
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2.4 Discussion
In the present study we have established a clinically relevant model of melanoma brain
metastases and characterized the appearance and size of metastases using MRI. To the best
of our knowledge this is the first study to use MRI to monitor the development of melanoma
brain metastases longitudinally. This is also the first report of the use of bSSFP to image
melanoma brain metastases. This model was achieved using an injection of 50,000 A2058
human melanoma cells into the left ventricle of the heart in nude mice and resulted on
average, 13 brain metastases per mouse. Metastases were detected throughout the mouse
brain; the majority was parenchymal, but meningeal metastases were also common.

There are relatively few animal models of brain metastases. The more conventional
experimental metastasis models use tail vein injection for hematogenous delivery and most
cells are trapped in the lung; the first organ encountered with an extensive capillary bed.
Brain metastases rarely develop, in part because mice with lung metastases do not survive
long enough. This issue is circumvented with an intracardiac (IC) injection. The initial
distribution of cells after the IC injection depends on cardiac output, therefore a portion of
the cells colonize the brain as it is the first capillary bed to be reached. This model captures
several mechanisms fundamental to metastatic growth: survival in the circulation, arrest in a
secondary organ, extravasation into the target organ tissue and colonization in the distant
metastatic site. We have previously used this approach to study brain metastases due to
breast cancer (37-40). The Steeg lab, with whom we collaborate, has used this model
extensively to study the molecular mechanisms and treatments for brain metastasis (41-44).
The IC cell injection method has been used to induce melanoma brain metastases in a small
number of studies, mostly using the B16 mouse melanoma cell line (45,46). Other models of
melanoma brain metastasis have used an intracarotid (ICA) cell injection or direct intracranial implantation of cells, both of which require surgical manipulation (18,47-54).

MRI was used to determine the types, numbers and volumes of brain metastases due to
melanoma. In bSSFP images most melanoma brain metastases appeared slightly or
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moderately hyperintense compared to the surrounding brain tissue. Occasionally, metastases
appeared hypointense, more often at late time points. Our histology also revealed that not all
metastases were detected by bSSFP MRI, and looking back retrospectively we found that
some metastases were isointense with the surrounding brain tissue and therefore
inconspicuous. This presents as a limitation in our study since metastatic burden is higher
than what is previously reported in our study at various imaging time points. The variable
MRI appearance of melanoma brain metastases is consistent with what is reported clinically
and is based largely on the degree of melanin and the presence or absence of hemorrhage
(55-58).

In patients, classic melanotic melanoma appears hyperintense on T1wSE images and
hypointense on T2wSE (57). This is because melanin is a paramagnetic species, which
shortens both T1 and T2 relaxation times (in SE images shorter T1 means brighter, shorter
T2 means darker). Since the amount of melanin varies between melanoma brain metastases
the amount of contrast can vary. Amelanotic melanoma metastases appear hypo- or isointense on T1w images and hyper- or iso-intense on T2w images (57).

Hemorrhage has strong effects on the MR signal and contrast due to hemorrhage is even
more complicated because as the hemorrhage evolves the oxidation state of the hemoglobin
molecule changes and the red blood cell (RBC) membranes lyse (59-61). It is the iron moiety
of the hemoglobin that influences changes in the MR signal. In the early subacute stage (few
days), deoxyhemoglobin (deoxy-Hb) in the intact RBC oxidizes to methemoglobin (Met-Hb).
Iron is in the ferric oxidation state (Fe3+); it has five unpaired electrons and is paramagnetic.
In addition the configuration of Met-Hb allows water molecules to come into close contact
with the unpaired electrons. At this stage Met-Hb is intracellular. Water molecules move
freely across the cell membrane and can thus approach close enough for T1 shortening
effects to occur. In addition the inhomogeneous distribution of intracellular metHb results in
local magnetic field inhomogeneities and so T2 relaxation shortening. In the late subacute
stages (4-7 days to 1 month), RBC cell lysis occurs and Met-Hb is now extracellular; Met-Hb
is surrounded by water protons, which leads to profound T1 shortening. However, because
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Met-Hb in solution is homogeneously distributed T2 shortening is less significant. At the
chronic stage of hemorrhage (weeks to years) hemosiderin is present in macrophages.
Hemosiderin is insoluble and has a large number of unpaired electrons and is
superparamagnetic. Because it is insoluble in solution water protons cannot approach close
enough for T1 shortening effects to occur. Conversely, the inhomogeneous distribution of
this powerful superparamagnetic leads to profound T2 shortening. Two or more of the
hemoglobin compounds are often present concurrently in a hemorrhage making MRI contrast
complex.

Contrast in bSSFP images is related to T2/T1. Our observation of slightly or moderately
hyperintense brain metastases could be due to melanin content and/or hemorrhage.
Depending on the melanin content, the degree of T1 shortening (hyperintensity) will be
variable. (See Appendix G for melanoma brain metastases that contain melanin
pigmentation). The observation of isointense metastases might be due to simultaneous T1
and T2 shortening. Alternatively this could be due to the absence of melanin (amelanotic)
and blood degradation products in brain metastases. The hypointense metastases we observed
with bSSFP are most likely due to blood degradation products such as hemosiderin. Due to
observation of hemorrhage from histological analysis it would suggest that hemorrhage is
most likely the main contributor to a decrease in signal.

Through the use of two MRI sequences, bSSFP and Gd-DTPA-enhanced T1wSE, we were
able to evaluate the metastatic tumour burden and the integrity of the BTB over time as
metastases developed in the brain. There were two major findings from this work. First, there
is considerable heterogeneity in the permeability of melanoma brain metastases in this
model. Second, the bSSFP sequence enabled the detection of brain metastases that were not
detected (i.e. did not enhance) in post Gd-DPTA T1wSE images.

The presence of substantial heterogeneity of the BTB in our study suggests that differences in
permeability may have an effect on how well chemotherapeutics are able to permeate the
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BTB. Thus enhancing metastases are different amongst each other. We are not the first to
report heterogeneity in permeability of brain metastases. Zhang et al. used intravenous
sodium fluorescein and histology to show that there was variability in the BBB permeability
of brain metastases generated in mice from 8 different human cancer cell lines (breast, colon,
renal and melanoma) (18). Lockman et al. demonstrated that breast cancer brain metastases
in nude mice showed a range of values for passive permeability to the 3kDa tracer Texas red
fluorescent dextran (16). While most metastases (~90%) showed increased permeability
compared to normal brain, the degree of permeability of brain metastases varied widely and
was much lower than that measured in peripheral tumours. This work was followed up by an
in vivo MRI study conducted by Percy et al., in our lab (17). Percy et al. showed that no
enhancing metastases were visualized at the early time point with T1wSE using Gd-DTPA. A
wide range of volumes for enhancing and nonenhancing metastases was observed and it was
also shown that metastasis volume and growth rates did not dictate whether or not a
metastasis would become enhanced. In this thesis we have expanded on these findings by
looking at brain metastases due to melanoma, and by including an additional imaging time
point to improve the temporal sampling in vivo.

To understand why differences in permeability exist between metastases we first looked at
whether their size or location in the brain was predictive of permeability. We found no
relationship between location in the brain and enhancement after Gd-DTPA. Although the
size of metastases increased with time we found no significant difference in the volumes,
measured from MRI, for enhancing and nonenhancing metastases at any imaging time point.
These findings are very similar to what was previously observed by Percy et al., for brain
metastases due to breast cancer (17). Lockman et al. also reported no clear relationship
between the diameter of brain metastases, measured by histology, and the degree of
permeability to dextran (16). Our results, however, contradict other studies that have looked
at the relationship between tumour size and BBB integrity since we observed no clear
relationship between size and permeability.
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An early study by Hasegawa et al. used phosphorescence imaging and radioactive alphaaminoisobutyric acid (AIB) to show that the permeability of breast cancer brain metastases in
the rat varied with the size of the tumor (62). Parenchymal tumors less than 1 mm in diameter
showed no increased permeability to AIB. As the tumors enlarged over 1 mm in diameter,
the permeability increased proportionally. Permeabilities of these brain metastases were less
than one-third of the permeability of subcutaneously transplanted breast tumors. The results
of Zhang et al., suggest that the permeability of the BTB is related to both the growth
pattern/morphology and the size of the metastases. They showed that brain metastases were
not permeable until they formed large masses (>0.2 mm); this was true for 2 different tumour
morphologies; solid nodules and diffuse clusters of cells that eventually coalesced (18).

Historically, changes to the integrity of the BTB have been associated with large brain
tumours (1-4 mm), which become oxygen and nutrient deprived and develop angiogenic
vessels (63-65). Our data, however, clearly show that even very small metastases may be
leaky. The differences between our results and those of others may be related to a number of
factors including: differences in the specific tracer or contrast agent used, the cell lines and
the timing of the interrogation of tumours. Together all of these studies reveal a complex
relationship between metastasis size and permeability.

To investigate differences amongst enhancing and nonenhancing brain metastases, future
studies may focus on examining molecular markers involved with maintenance of BBB
integrity and function. Claudin-5, Occludin and ZO-1 could be tested in combination with
endothelial markers such as CD31 and CD105 (endoglin) (66-69) to determine which
tumours are undergoing angiogenesis. An interesting finding from the Lockman study was a
relationship between overexpression of desmin pericyte protein, a component of the BTB.
Other markers such as BRAF, STAT3, b-FGF, VEGF, GLUT-1 (70-73) may also be useful
for molecular analysis to delineate differences between these types of metastases.
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It has been demonstrated in other studies (19,29) that tumour vessel co-option does not cause
disturbance to the endothelium of the BBB and the barrier remained intact as metastasis were
not visible in contrast enhancement (CE) using Gd-DTPA. This might explain why some
metastases in our study were nonenhancing. Two reasons that could explain the presence of
enhancing metastases in our study are that 1) some could be secreting VEGF while remaining
co-opted to pre-existing cerebral blood vessels and 2) some metastases remaining co-opted
could be secreting VEGF and inducing angiogenesis. There is also the possibility that
different vascularization processes such as vessel co-option, angiogenesis, and vasculogenic
mimicry (74-76) are occurring simultaneously and may be influencing or controlling the
transition to enhancement in a metastasis.

T1wSE with Gd-DTPA is the gold standard for brain tumour imaging in the clinic (58,77).
Therefore, the fact that bSSFP detected nonenhancing metastases has important clinical
implications. Our findings suggest that some metastases may go undetected by T1wSE with
Gd-DTPA imaging. This warrants further study of bSSFP and its ability to detect small,
nonpermeable metastases. We also observed that some melanoma brain metastases appeared
as isointense in bSSFP, this presents as a problem since some metastases are missed as well
in bSSFP images in the case of melanoma, due to its variable appearances in MRI. Future
work by our lab will compare bSSFP to the conventional MRI pulse sequences in a clinical
setting, to evaluate the possibility of improving early detection of brain metastases.

Brain metastases are an important clinical problem. Brain metastases contribute to death in
nearly 95% of melanoma patients, with a median survival of less than 1 year despite
treatment (2,78). There has been little improvement in this prognosis during the last 3
decades but new approaches are on the horizon. Preclinical models of metastatic disease
provide a platform for the development and testing of new treatments and preclinical MRI is
well suited to aid in the acceleration of these discoveries. The MRI methods used in this
thesis to image brain metastases in mice is directly applicable to human studies. Future work
in our lab will use this model to compare the in vivo response of BBB permeable and
nonpermeable brain metastases to chemotherapeutics and radiation therapy. These
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experiments will improve our understanding of the effects of treatment on tumour
permeability and assist in the development of more effective treatments that could lead to
better clinical management of patients with brain metastases.
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Chapter 3

3

Study Implications and Future Directions

3.1 Summary of Key Findings
This study used a noninvasive magnetic resonance imaging approach to establish and
characterize a clinically relevant mouse model of melanoma brain metastasis. To the best of
our knowledge, this is the first study to characterize a clinically relevant model of melanoma
brain metastasis using MRI. This model was then implemented in longitudinal MRI
permeability studies. Using an established MRI-based protocol for detection of enhancing
and nonenhancing brain metastases (1) we were able to monitor alterations in the bloodtumour barrier (BTB), and measure metastasis volume. Histological analysis was used to
compare permeability findings with in vivo permeability findings and examine differences in
metastasis morphology. Five key findings from this project are summarized below.

3.1.1. Characterized Model of Melanoma Brain Metastasis using MRI
An intracardiac injection of 50,000 human melanoma cells produced 5-19 brain metastases
per animal. Meningeal and parenchymal metastases were detected, mimicking the human
disease. In the clinically relevant model we have characterized, mice showed signs of
neurological deficits such as hemiplegia (paralysis of one side of the body). Intracranial
hemorrhage was apparent as well as the manifestation of hemorrhagic metastases (See
Appendix E for MRI image and photographs showing hemorrhage). Hydrocephalus was also
observed in the T1wSE and bSSFP MRI images.
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3.1.2. Longitudinal Magnetic Resonance Imaging Studies: Early Detection of Melanoma
Brain Metastases using bSSFP
Our main observation was that many metastases detected at the early time point (day 22)
using bSSFP were nonenhancing, whereas only two metastases were shown as enhancing at
the early time point (day 21) using T1wSE with Gd-DTPA. Interestingly, the number of
metastases detected at the early time point using T1wSE with Gd-DTPA was never greater
than one per animal. Most metastases detected at the early time point (day 22) were
nonenhancing and many were small in volume ranging from 0.0247mm3 to 0.0906mm3.

3.1.3. Longitudinal Magnetic Resonance Imaging Studies: Variability in Enhancement and
Patterns of Enhancement
Substantial heterogeneity in enhancement of brain metastases was observed throughout the
study (Table 2.3.1 experiment 2;groups 1&2); each mouse had different numbers of
enhancing metastases. Also, various patterns of enhancement were also observed (Chapter 2,
figure 2.3.15) in different mice with melanoma brain metastases. Some metastases first
appeared as nonenhancing and switched to enhancing at later time points; whereas, others
that first appeared as enhancing remained enhancing throughout the experiment. There was
one instance where a detected metastasis remained nonenhancing for the course of the study.
Thus from these observations it would suggest that metastasis enhancement is a
heterogeneous event with respect to the BTB.

3.1.4. Longitudinal Magnetic Resonance Imaging Studies: Volume, location and Age of
Enhancing and Nonenhancing Brain Metastases
Using the MRI-based protocol established by Percy et al. (1) a range of volumes were
measured for enhancing and nonenhancing metastases. We observed that there was no
difference between the volume of enhancing and nonenhancing metastases at any time point.
There was also no clear relationship between brain location and enhancement. In terms of
age (when it was first detected to experimental endpoint) of the metastasis, metastases
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detected for the first time at the late time point were nonenhancing and some were large and
small in volume. Some metastases that were first detected as enhancing were also small in
volume. From these longitudinal analyses we have observed that there is no direct correlation
or relationship between volume, brain location or age of the metastasis and metastasis
enhancement. To the best of our knowledge this is the first study using a noninvasive
longitudinal imaging approach to investigate alterations of the BTB in melanoma brain
metastases.

3.1.5 Histology: Ex vivo Permeability vs. In vivo Enhancement
We observed, in most cases, disagreement between the permeability of dextran and the
contrast enhancement of metastases in T1wSE MRI images. For the nonenhancing
metastasis, there were trace amounts of dextran leakage into the tumour interstitial regions,
which we did not expect. This finding indicated that the BTB in certain regions of
nonenhancing metastases is not completely intact. Ex vivo permeability analysis was
performed to validate our in vivo MRI enhancement data. Dextran Texas Red was used as the
ex vivo permeability tracer in this study.

3.2 Biological Explanations of Metastasis Enhancement
Biological factors speculated to be involved with alterations of the BTB include: 1) BTB
modulation by vascular endothelial growth factor (VEGF)-A, 2) alteration in structure of the
blood-brain barrier (BBB) and 3) enzymatic activation and cell-cell communication.

3.2.1 BTB Modulation by VEGF-A
VEGF-A is an important proangiogenic protein factor necessary for the promotion of
angiogenesis. VEGF-A also functions to induce hyperpermeability and vasodilation in blood
vessels (2-4). In the present study we did not evaluate which tumours were undergoing
angiogenesis. Oliver et al. used A2058 human melanoma cells in, in vitro co-cultures and in
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vivo animal studies to demonstrate that VEGF and interleukin-8 (IL-8), (another
proangiogenic factor), were actively secreted (5). This indicates that this cell line has the
potential to be angiogenic and may use angiogenesis as another means to obtain blood
supply. In our study it is plausible that VEGF secretion might be involved with permeability
changes of the BTB.

3.2.2 Alteration in Structure of the BBB
Pericytes function to control the permeability and integrity of the BBB and are also involved
in communication via gap junctions (through which soluble factors transverse) with
endothelial cells and other cells of the BBB (6,7). It has been shown that a loss of pericytes in
the brain is associated with an increase in permeability (6,7). Astrocytes are similarly
involved in regulating BBB integrity and studies have revealed that selective loss of
astrocytes results in altered BBB function through changes in expression of tight junction
(TJ) protein(s) (8). In our study the fact that some metastases changed to enhancing would
suggest that astrocytic loss was prevalent. This warrants further investigation and could be
evaluated using glial fibrillary acidic protein (GFAP) staining to confirm the presence or
absence of astrocytes within or surrounding the BTB.

3.2.3 Enzymatic Activation and Cell-Cell Communication
Proteolytic enzymes are degradative enzymes secreted by cells to breakdown the local
extracellular matrix (ECM) (9). These enzymes have been implicated in cancer metastasis
during the intravasation process and in the initiation of BBB damage after extravasation (10).
Fazakas et al. demonstrated that one of the mechanisms of transmigration for A2058 and
B16F10 melanoma cells into the brain parenchyma was via the paracellular migration
pathway (movement through interendothelial TJ) (11). The authors observed that gelatinotic
serine protease secretion by the melanoma cells caused interendothelial TJ disruption as well
as endothelial cell apoptosis (11). Interestingly it has been reported that the presence of
matrix metalloproteinase 9 (MMP-9) is also involved with BBB impairment in brain trauma
injury (12). MMP-9 expression by perictytes, astroctyes and cerebral endothelial cells
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typically occurs during pathological conditions (6). This suggests that the secretion of
various proteases and proteinases may play a role in the induction of damage to the BBB
through degradation of TJs.

Astrocytes, perivascular macrophages, and neurons have been shown to be involved in BBB
induction processes (13). In vitro studies have shown that astrocyte-endothelial cell
interactions are important for mediation of unique characteristics towards the BBB (13).
Astrocytes are known to secrete agents such as transforming growth factor beta (TGF-β) and
basic fibroblast growth factor (bFGF) which are important for the induction process (a cellcell communication process) in which the endothelium becomes specialized (13). Estrada et
al. and Mi et al. had demonstrated the importance of soluble factors produced from cerebral
vessels for induction of growth and differentiation of astrocytes (14,15). This would suggest
that during pathological conditions there is loss of normal barrier induction cell-cell
communication signals from astrocyte to endothelium and the converse endothelium to
astrocyte. Hence it is possible that in the (BTB) there are alterations in the induction process
between astrocyte and endothelium and vice versa.

3.3 Impact of Key Findings
Early detection of brain metastases is important for proper patient management and
treatment. The presence of nonenhancing brain metastases at early time points that would not
be detected in current clinical imaging protocols (using T1wSE with Gd-DTPA) suggests the
need for improved clinical imaging. Furthermore, current treatments rely on permeating the
compromised BTB. However, Lockman et al. demonstrated that the extent of permeability
for breast cancer brain metastasis varied (16). In our preclinical study we also showed that
not every metastasis detected showed enhancement, and the timing of enhancement for the
metastases was variable. Thus, the heterogeneity of enhancement should be considered in
treatment planning because our assessment of brain metastases has shown that not all large
metastases are necessarily permeable and some small metastases do show permeability.
Another important point to consider is that even if a metastasis is permeable this does not
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necessarily mean that a chemotherapeutic drug will be able to extensively permeate the BTB.
This suggests the need for better therapeutic treatments that will be able to circumvent an
intact BTB.

3.4 Study Limitations
In this study we have shown that MRI can be used to characterize a clinically relevant model
of brain metastasis; there are however some limitations that should be addressed. First, the
two MRI scans were performed on different days so there is the potential for a change in
tumour characteristics in this time. This was done because Gd-DTPA takes 24 hrs to clear
from the mouse circulation thus we have to wait for this clearance before imaging using
bSSFP. From a clinical standpoint it would be more efficient and convenient to perform
scans on the same day. Also the optimized T1wSE sequence that is used in our study uses 11
slices thus some enhancing metastases might be missed since only a certain portion of the
mouse brain is covered. From a practical approach it would be worthwhile to increase the
image slice numbers to allow for better coverage of the entire mouse brain. This however
would mean that our scan time would be increased as well.

The sensitivity of our study was limited by image resolution. The highest resolution achieved
by our MRI scans was 100-µm in plane. Thus we were not able to see smaller metastases i.e.
micrometastases and therefore our MRI protocols underestimate the total number of
metastases detected. Also, some metastases presented as isointense on bSSFP images and we
did not count them because they were not visible. However, these metastases were visible in
H&E histology, which would help to validate the presence of a metastasis.

Gadopentatic acid (Gd-DPTA) is used in the clinical setting and is typically administered by
a bolus intravenous (IV) injection (17). In our model the intraperitoneal (IP) injection route
was used because our T1wSE scans were 15 min and if we were to inject Gd-DTPA by the
intravenous (IV) route the wash-in and washout times of Gd-DTPA are rapid 3min - 4min.
Lastly, in this disease model it was difficult to maintain longevity of mice for longitudinal
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studies since they were exhibiting disease onset by week 3 and most were dying at week 4,
which is when the longitudinal studies would commence. Thus larger batches of mice are
required for imaging during longitudinal studies of melanoma brain metastasis. Another
option would be to include additional earlier time points in the longitudinal study.

3.5 Future Directions
Areas of interest for future investigations of this project include: histological characterization
of enhancing and nonenhancing melanoma brain metastases, use of this model for testing
chemotherapeutic potential or efficacy in treating brain metastases. And lastly, the use of
bSSFP as an addendum clinical sequence for detection of nonenhancing metastases in the
clinical setting, and using other future MRI studies for studying enhancing and nonenhancing
brain metastases.

3.5.1

Histological

and

Immunohistochemical

Characterization

of

Enhancing

and

Nonenhancing Melanoma Brain Metastases
An important area of future research for melanoma brain metastases is the
immunohistochemical characterization of enhancing and nonenhancing melanoma brain
metastases using angiogenic and BBB markers. By further investigating markers that are
uniquely expressed and associated with enhancing and nonenhancing brain metastases,
respectively, we will be able to gain a better understanding of their inherent differences.
Ultimately we believe that this will help to propel better treatment planning in terms of drug
development. Molecular factors that would be of interest for testing include BRAF which is
involved with growth, survival, VEGFA and STAT3 which are involved with angiogenesis,
and GLUT-1, which is involved with BBB development.

It would also be interesting to histologically evaluate tissue sections corresponding to
contrast enhancing and nonenhancing brain metastases visualized by MRI at each time point.
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This would permit us to compare tissue morphologies over time and examine whether subtle
differences exist between tumour types that were not evident at the experimental endpoint.

3.5.2 Testing Therapeutic Efficacy using a Clinically Relevant Model
The goal of treatment, is to treat metastases as early as possible; however, the reality is that
most brain metastases are detected at later stages of disease. The clinically relevant model we
have established has the potential to be used in testing the efficacy of novel chemotherapeutic
agents and in the evaluation of alternative methods for delivery of chemotherapeutic agents
to target sites. Use of this model would aid tremendously in observing how melanoma brain
metastases would respond to these therapies and potency of these drugs. Also there is the
potential of this model to be used with other therapeutic modalities such as radiotherapy,
radiosurgery, immunotherapy and targeted therapy (19,20). This model could also be used
for different stages of disease onset. We are confident that this clinically relevant model of
melanoma has the potential to be used in the evaluation of new treatment options.

We also aim to use this model to test the efficiency of alternative methods for drug delivery
across the intact BBB. Some attractive proposed mechanisms include the use of neural
stem/progenitor cells (NSPCs) loaded with 5-fluorocytosine (5-FC) pro-drug (inactive drug)
of the chemotherapeutic agent and NSPCs loaded with the enzyme cytosine deaminase (CD)
used to activate the pro-drug (21). Nanocarriers/nanoparticles such as poly (n-butyl
cyanoacrylate) (PBCA) (22) and polyethylene glycol (PEG) liposomal nanocarriers (23) are
being developed as vehicle agents for drug delivery. Focused ultrasound (FUS) guided MRI
techniques have also been used as a method to temporarily disrupt the BBB (24,25). Our
model could be used to test the delivery and efficacy of these new drug carrier methods.

3.5.3 Translation of the bSSFP Pulse Sequence for Brain Metastasis Detection in the Clinic
The goal of establishing a clinically relevant animal model is to be able to translate
preclinical findings to the clinical setting. Currently no reports in the literature have shown
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bSSFP used for the detection of human melanoma metastases in visceral organs or the brain.
We have shown that nonenhancing metastases are detectable on bSSFP images at early time
points. This reinforces the need to use alternative clinical sequences because brain metastases
that do not enhance may be missed using current brain metastasis detection methods. Also
another important point to mention is that amelanotic melanoma brain metastases may also
appear isointense in T1w and T2w images as well as in bSSFP. Thus, if these metastases do
not enhance using Gd-DTPA then they would most certainly be missed in brain metastasis
detection. The implementation of bSSFP in clinical imaging protocols would increase the
potential for earlier detection of nonenhancing metastases. However, this would only apply to
metastases that do not appear isointense (in the case of melanoma brain metastases).

3.5.4. Future MRI Studies for Melanoma Brain Metastases
In future MRI studies we would like to use iron oxide contrast agents to evaluate the
vascularity of enhancing and nonenhancing brain metastases. As a pilot project, we have
imaged two mouse brains at day 14 and day 31 pre- and post-USPIO (Molday) contrast
agent. Analysis of post-contrast imaging showed that blood vessels were present and some
appeared to be dilated. (See Appendix F for bSSFP images with pre- and post-Molday
contrast agent).
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Appendices
Appendix A: Animal Use Protocol
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Appendix B: Inter and Intra observer metastasis volume measurements
The reliability of metastasis volume measurements was determined by inter observer and
intra observer volume measurement using the manual trace method. Agreement indices (see
references Chapter 2 Filipi et al. and Joe et al.) and percentage differences were used to
calculate the closeness in average metastatic volume measurements for the reference observer
versus vs. outside observer as well as the reference observer vs. reference observer.

The percentage difference equation used was as follows:
larger number - smaller number x 100
smaller number

The following equation was used to obtain the inter- and intra-observation reliability
measurements (agreement indices) for metastasis volumes:
For inter-observation
larger number= observer 2 (outside observer)
smaller number= observer 1 (reference observer; myself)

For intra-observation
larger number= observer 1 (same individual; myself)
smaller number= observer 1 (same individual; myself)
The agreement index (AI) used (Filipi et al. Brain 1995) is as follows:
AI (agreement index) inter-observer agreement index = 1- |Xa - Xb|
(Xa + Xb)/2
AI intra-observer agreement index= 1- |X1st - X2nd|
(X1st + X2nd)/2
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The closer the agreement indices are to 1 the better the correlation.
Both inter- and intra-observer tumour metastasis measurements showed high agreement
indices. Thus with confidence we can be assured that the measurements obtained for
metastasis volumes in this thesis project are reliable measurements.

Example of inter-observation metastasis volume measurements graphical correlation (Mouse
ID 1, N=11 metastases)
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Example of intra-observation metastasis volume measurements graphical
correlation (Mouse ID 2, N=4 metastases)

We see that intra-observation provided good correlation with volume
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Appendix C: Total metastatic burden
The data in this table shows the total metastatic burden for each mouse at different time
points during the longitudinal study. Metastatic burden for each mouse increased over time.
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Appendix D: Total, mean metastasis number, and mean volumes for meningeal
and parenchymal brain metastasis
This table shows the total number of meningeal and parenchymal metastasis, the mean
numbers and volumes for meningeal and parenchymal metastasis.
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Appendix E: Melanoma brain metastases hemorrhage
The following are examples of hemorrhage observed in the mouse brain from MRI image
and removal of mouse brain after mouse sacrifice.

Clinically relevant model endpoint day 25: intracerebral hemorrhage observed in bSSFP
image (A, yellow arrowhead) and H&E histology (B, black arrows), white arrows in B
indicate presence of neutrophils. The nucleus of neutrophils is segmented (lobed nuclei) or
band form (curved or half-moon appearance).

Longitudinal study endpoint day 31: Brain hemorrhage (C, D white arrows) for two different
mouse brains.
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Appendix F: Pilot study using USPIO (Molday) for tumour vasculature analysis
bSSFP image day 14: (pre and post Molday contrast agent injection)

bSSFP day 31: (pre and post Molday contrast agent injection)

Figure Appendix G: Shown are bSSFP images from different mice. (A&B) pre and post
Molday bSSFP images of mouse brain at day 14; in (A) no metastases are visible at day 14.
In (D) both enhancing metastases (yellow arrows) displayed differences in vascularization at
day 31. Post molday injection (D) shows blood vessels containing molday label (white
arrows).
Using bSSFP, pre and post Molday images were acquired. There was a noticeable difference
in the pre and post images. In the post Molday images, brain vasculature as well as
vasculature within the brain metastasis were seen as regions of hypointensity (loss of signal).
We also wanted to look at patterns of vascularization of brain metastases using the Molday
iron contrast agent at day 14 and day 31. At day 14 (A&B) no metastases were observed and
only the brain vasculature was outlined with Molday contrast agent. It was observed that the
vasculature of the metastases (D) was clearly outlined with the Molday as opposed to the pre
Molday imaging. In (D) both of these metastases (yellow arrows) were found to be
enhancing with Gd-DTPA at day 31, the blood vessels in the larger metastasis were much
easier to see compared to the smaller metastasis at the top of the brain. Post Molday
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intravenous (IV) injection showed intratumoral as well as peritumoral vasculature among
some metastases (white arrows), also some of these vessels appeared to be larger and dilated
compared to other metastases. Throughout this mouse brain, some metastases appeared to be
more vascularized compared to others. Using Molday we were able to see more clearly the
metastasis vasculature and more importantly the pattern of vascularization.

bSSFP MRI parameters for pre and post Molday:
FOV = 1.5 , TR/TE=10/5 ms, FA= 35°, image matrix = 150 x 150, NEX= 4, rBW =±11.90
kHz, PC =4. The scan time was 38.25min and the spatial resolution was 100 x 100 x 200 µm.
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Appendix G: Melanin images
The following H&E images (from the same mouse brain) show the presence of melanin
pigmentation (A, yellow arrows) for a nonenhancing metastasis and an enhancing metastasis
(B,C yellows arrows)
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Appendix H: License and Permission usage
Nature Publishing Group License (Chapter 1)
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Elsevier License (Chapter 1)
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Springer License (Chapter 1)
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